Document:

EX-10.7

 Exhibit 10.7 

Form of Bottler’s Agreement 
 THIS
AGREEMENT, made and entered into with effect from                     , by and among THE COCA-COLA
COMPANY, a corporation organized and existing under the laws of the state of Delaware, United States of America, with principal offices at One Coca-Cola Plaza, N.W., in the City of Atlanta, State of Georgia
30313, United States of America; THE COCA-COLA EXPORT CORPORATION, a corporation organized and existing under the laws of the state of Delaware, United States of America, with principal offices at One Coca-Cola Plaza, N.W., in the City of Atlanta, State of Georgia 30313, United States of America (The Coca-Cola Company and The
Coca-Cola Export Corporation hereinafter collectively or severally referred to as the “Company” unless otherwise specified); and
                    , a                     
organized and existing under the laws of                     , with principal offices at
                    (hereinafter referred to as the “Bottler”). 

WITNESSETH: 
 WHEREAS, 

 

	A.	The Coca-Cola Company is engaged in the manufacture and the sale of beverage bases, essences, and other ingredients and a beverage base concentrate (hereinafter referred to as the
“Concentrate”), the formula for which is an industrial secret of The Coca-Cola Company, from which a non-alcoholic beverage syrup or powder (hereinafter
referred to as the “Syrup”) is prepared, and is also engaged in the manufacture and sale of the Syrup, which Concentrate or Syrup is used in the preparation of a non-alcoholic beverage product
(hereinafter referred to as the “Beverage”) for sale in bottles and other containers and in other forms or manners; 

  

	B.	The Coca-Cola Company is the owner of the trade marks including “Coca-Cola” and “Coke” that distinguish the
Concentrate, the Syrup, and the Beverage, the trade mark consisting of a Distinctive Bottle in various sizes in which the Beverage has been marketed for many years, the depiction of the Distinctive Bottle, the Dynamic Ribbon device, and the
intellectual property embodied in the distinctive trade dress, other design devices and packaging elements associated with the Concentrate, the Syrup and the Beverage (said trade marks “Coca-Cola”,
“Coke”, the Distinctive Bottle, the depiction of the Distinctive Bottle, the Dynamic Ribbon device, the intellectual property embodied in the distinctive trade dress, other design devices and packaging elements associated with the
Concentrate, the Syrup and the Beverage, and any additional trade marks that The Coca-Cola Company may adopt from time to time to distinguish the Concentrate, the Syrup and the Beverage being hereinafter
referred to as the “Trade Marks”); 

  

	C.	The Company has the exclusive right to prepare, package, distribute and sell the Beverage and the right to manufacture and sell the Concentrate in
                    , among other countries; 

  

	D.	The Coca-Cola Company has designated and authorized certain third parties to supply the Concentrate to the Bottler (said third parties being hereinafter referred to as the
“Authorized Suppliers”); 

  

					
		 		 	Page 1
		 		 	

	E.	The Bottler has requested an authorization from the Company to use the Trade Marks in connection with the preparation, packaging, distribution and sale of the Beverage in and throughout a territory as defined and
described in this Agreement; 

  

	F.	The Company is willing to grant the requested authorization to the Bottler under the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, the parties agree as follows: 
  

	I.	OBJECT OF THE AGREEMENT 

  

	 	1.	The Company hereby authorizes the Bottler, and the Bottler undertakes, upon the following terms and conditions, to prepare and package the Beverage in such containers as may be approved by the Company in writing from
time to time (hereinafter referred to as “Approved Containers”) and to distribute and sell the same under the Trade Marks, in and throughout the following territory (hereinafter referred to as the “Territory”): 

[TERRITORY DESCRIPTION] 
  

	 	2.	The Company or Authorized Suppliers will sell and deliver to the Bottler such quantities of the Concentrate as may be ordered by the Bottler from time to time, provided that the Bottler will order, and the Company or
Authorized Suppliers will sell and deliver to the Bottler, only such quantities of the Concentrate as may be necessary and sufficient to implement this Agreement. In this regard, the Bottler covenants and agrees to buy Concentrate only from the
Company or Authorized Suppliers. 

  

	 	3.	The Bottler will use the Concentrate exclusively for the preparation of the Syrup and the preparation and packaging of the Beverage as prescribed from time to time by the Company. The Bottler undertakes not to sell or
resell the Concentrate or the Syrup, nor permit the same to fall into the hands of third parties, without the prior written consent of the Company. 

  

	 	4.	The Coca-Cola Company retains the sole and exclusive right at any time to determine the formula, composition or ingredients for the Concentrate and the Beverage.

  

	 	5.	Except as may be provided herein and for the term of this Agreement, the Company will refrain from selling or distributing, or from causing the sale or distribution of, the Beverage in the Territory in Approved
Containers. The Company reserves the rights, however, to prepare and package the Beverage in any container in the Territory for sale outside the Territory, and to prepare, package, distribute or sell, or authorize third parties to prepare, package,
distribute or sell, the Beverage in the Territory in any container other than an Approved Container. 

  

					
		 		 	Page 2

	II.	OBLIGATIONS OF THE BOTTLER RELATIVE TO THE MARKETING, PLANNING AND REPORTING 

  

	 	6.	The Bottler covenants and agrees with the Company: 

  

	 	(a)	to make every effort and employ all practicable and approved means to promote, develop and exploit the full potential of the business of preparing, packaging, distributing, marketing and selling the Beverage throughout
the Territory by creating, stimulating and expanding continuously the future demand for the Beverage and by satisfying fully and in all respects the current demand therefor; 

 

	 	(b)	to prepare, package, distribute and sell such quantities of the Beverage as shall in all respects satisfy fully every demand for the Beverage within the Territory; however, with the prior written consent of the Company,
the Bottler may purchase the Beverage in Approved Containers from parties designated in writing by the Company for resale by the Bottler within the Territory; 

  

	 	(c)	to invest all the capital and to obtain and expend all the funds required for the organization, installation, operation, maintenance and replacement within the Territory of such manufacturing, warehousing, marketing,
distribution, delivery, transportation and other facilities and equipment as shall be necessary for the Bottler to comply with its obligations under this Agreement; 

 

	 	(d)	to provide competent and well-trained management and recruit, train, maintain and direct all personnel required, sufficient in every respect to perform all of the obligations of
the Bottler under this Agreement; 

  

	 	(e)	to deliver to the Company once in each calendar year a program or plan in writing acceptable to the Company as to form and substance and in accordance with the Bottler’s obligations under this Agreement, showing in
detail the activities of the Bottler contemplated for the ensuing twelve-month period or such other period as the Company may prescribe, to prosecute such program or plan diligently, and to deliver to the
Company upon its request written reports of the progress of the work in an acceptable form; 

  

	 	(f)	to report to the Company accurate and current information on production, distribution and sales of the Beverage at such intervals, in such detail and in such form as may be requested by the Company; 

 

	 	(g)	 to maintain accurate books, accounts and records and to provide to the Company such financial, accounting and
other information as the Company may request to enable the Company to determine whether the Bottler is maintaining the consolidated financial capacity reasonably necessary to 

  

					
		 		 	Page 3

	 	
perform its obligations under this Agreement and in recognition of the Company’s interest in maintaining, promoting and safeguarding the overall performance, efficiency and integrity of the
bottling, distribution and sales system; 

  

	 	(h)	not to sell and/or distribute the Beverage, without the prior written consent of the Company, outside the Territory or to anyone who intends to resell the Beverage outside the Territory; the foregoing prohibition does
not apply if the Territory is a Member State or within a Member State of the European Economic Area and the sale results from an order from a customer in another Member State or for export to another Member State; and 

 

	 	(i)	not to actively seek customers nor maintain a branch outside the Territory; however, the Bottler shall have the right to fill unsolicited orders for the Beverage from any customer located within another Member State or
for export to another Member State of the European Economic Area. 

  

	 	7.	The Bottler must, for its own account, budget and expend such funds for advertising, marketing and promoting the Beverage as may be reasonably required by the Company to create, stimulate and sustain the demand for the
Beverage in the Territory, provided that the Bottler shall submit all advertising, marketing and promotional projects relating to the Trade Marks or the Beverage to the Company for its prior approval, and shall use, publish, maintain or distribute
only such advertising, marketing or promotional material relating to the Trade Marks or the Beverage as the Company shall approve and authorize. The Company may agree from time to time and subject to such terms and conditions as it shall stipulate
in each case to contribute financially to the Bottler’s marketing programs. The Company may also undertake, at its own expense and independently from the Bottler, any additional advertising or sales promotion activities in the Territory it
deems useful or appropriate. 

  

	 	 8.      (a)	The Bottler recognizes that the Company has entered into or may enter into agreements similar to this Agreement with other parties outside the Territory and accepts the limitations such agreements may reasonably impose
on the Bottler in the conduct of its business under this Agreement. The Bottler further agrees to conduct its business in such a manner so as to avoid conflicts with such other parties, and, in the event of disputes nevertheless arising with such
other parties, to make every reasonable effort to settle them amicably. 

  

	 	(b)	The Bottler will not oppose any additional actions the adoption of which are considered by the Company as necessary and justified in order to protect and improve the sales and distribution system for the Beverage,
including, but not limited to; those actions which might be adopted concerning the supply of large and/or special customers whose field of activity transcends the boundaries of the Territory, even if such actions should limit the Bottler’s
rights under this Agreement, including measures taken in compliance with the Rules of Competition of the European Union. 

  

					
		 		 	Page 4

	 	9.	The Bottler, recognizing the important benefit to itself and all the other parties referred to in Clause 8(a) above, of a uniform external appearance of the distribution and other equipment and materials used under this
Agreement, agrees to accept and apply the standards adopted and issued from time to time by the Company for the design and decoration of trucks and other delivery vehicles, cases, cartons, coolers, vending machines and other materials and equipment
used in the distribution and sale of the Beverage. 

  

	 	10.	The Bottler acknowledges and agrees that the broadest possible direct distribution and sale of the Beverage to retail outlets and final consumers in the Territory is an essential element in satisfying fully the demand
for the Beverage pursuant to this Agreement. Notwithstanding the recognized advantages of direct distribution, the Bottler shall be authorized to distribute and sell the Beverage to wholesalers in the Territory who sell only to retail outlets in the
Territory. Any other methods of distribution shall be subject to the prior written consent of the Company. 

  

	 	 11.    (a)	In the event any of the Beverage prepared, packaged, distributed or sold by the Bottler is found either in the territory of another authorized bottler or authorized distributor within
                     or in the territory of another authorized bottler or authorized distributor within a state that is not a Member State of the
European Economic Area (hereinafter referred to as the “Injured Bottler”), then, in addition to all other remedies available to the Company: 

  

	 	(1)	if the phenomenon persists or reoccurs after the Company has requested the Bottler, in writing, to end or prevent it, by discharging the Bottler’s obligation under Clauses 6(h) and (i), the Company may, in its sole
discretion, cancel forthwith the approval for the container(s) of the type which were found in the Injured Bottler’s territory; 

  

	 	(2)	the Company may charge the Bottler an amount of compensation for the Beverage found in the Injured Bottler’s territory, to include all lost profits, expenses and other costs incurred by the Company and the Injured
Bottler; and 

  

	 	(3)	the Company may purchase any of the Beverage prepared, packaged, distributed or sold by the Bottler which is found in the Injured Bottler’s territory, and the Bottler shall, in addition to any other obligation it
may have under this Agreement, reimburse the Company for the Company’s cost of purchasing, transporting and/or destroying such Beverage. 

  

	 	(b)	In the event the Beverage prepared, packaged, distributed or sold by the Bottler is found in the territory of an Injured Bottler, the Bottler shall make available to representatives of the Company all sales agreements
and other records relating to the Beverage and assist the Company in all investigations relating to the sale and distribution of the Beverage outside the Territory. 

 

	 	(c)	The Bottler shall immediately inform the Company if at any time any solicitation or offer to purchase the Beverage is made to the Bottler by a third party which the Bottler knows or has reason to believe or suspect
would result in the Beverage being marketed, sold, resold, distributed or redistributed outside the Territory in breach of this Agreement. 

  

					
		 		 	Page 5

	III.	OBLIGATIONS OF BOTTLER RELATIVE TO THE TRADE MARKS 

  

	 	12.	The Bottler will at all times recognize the validity and ownership of the Trade Marks by The Coca-Cola Company and will not at any time put in issue the validity and ownership of
the Trade Marks. 

  

	 	13.	Nothing herein shall give the Bottler any interest in the Trade Marks or the goodwill attaching thereto or in any label, design, container or other visual representations thereof, or used in connection therewith; and
the Bottler acknowledges and agrees that all rights and interest created through such usage of the Trade Marks, labels, designs, containers or other visual representations shall inure to the benefit and be the property of The Coca-Cola Company. The Coca-Cola Company and the Bottler agree and understand that the Bottler under this Agreement is obligated to use said Trade Marks, labels, designs,
containers or other visual representations thereof, in connection with the preparation, packaging, distribution and sale of the Beverage in Approved Containers without the payment of any fee; said use to be in such manner and with the result that
all goodwill relating to the same shall accrue to The Coca-Cola Company as the source and origin of such Beverage, and the Company shall be absolutely entitled to determine in every instance the manner of presentation and such other steps necessary
or desirable to secure compliance with this Clause 13. 

  

	 	14.	The Bottler shall not adopt or use any name, corporate name, trading name, title of establishment or other commercial designation which includes the words “Coca-Cola”,
“Coca”, “Cola”, “Coke”, or any of them, or any name that is confusingly similar to any of them, or any graphic or visual representation of the Trade Marks or any other trade mark or intellectual property owned by The Coca-Cola Company, without the prior written consent of The Coca-Cola Company. 

  

	 	15.	The Bottler covenants and agrees during the term of this Agreement and in accordance with applicable laws: 

  

	 	(a)	not to manufacture, prepare, package, distribute, sell, deal in or otherwise be concerned with any product associated with any trade dress or any container that is an imitation of a trade dress or container in which the
Company claims a proprietary interest or which is likely to be confused with or cause confusion or be perceived by consumers as confusingly similar to or be passed off as such trade dress or container; 

  

					
		 		 	Page 6

	 	(b)	not to manufacture, prepare, package, distribute, sell, deal in or otherwise be concerned with any product associated with any trade mark or other designation which is an imitation or infringement of any of the Trade
Marks or is likely to cause passing-off of any product which is intended to lead the public to believe that it originates with the Company because of the Bottler’s association with the business of
manufacturing, preparing, packaging, distributing and selling the Beverage; without in any way limiting the generality of the foregoing, it is hereby expressly understood and stipulated that use of the word “Coca” or local language or
phonetic equivalent in any form or fashion, or any word graphically or phonetically similar thereto or in imitation thereof, on any product other than that of The Coca-Cola Company would constitute an
infringement of the trade mark “Coca-Cola” or be likely to cause passing-off; 

 

	 	(c)	not to use delivery vehicles, cases, cartons, coolers, vending machines and other equipment bearing the Trade Marks for the distribution and sale of any products which are not identified by the Trade Marks without the
prior written consent of the Company; 

  

	 	(d)	during the term of this Agreement and for a period of two (2) years after its termination not to manufacture, prepare, package, distribute, sell, deal in or otherwise be concerned with any other concentrate,
beverage base, syrup, or beverage which is likely to be confused with or passed off for the Concentrate, Syrup or Beverage; and 

  

	 	(e)	not to acquire or hold, directly or indirectly, any ownership interest in, or enter into any contract or arrangement with respect to the management or control of any person or legal entity, within or outside of the
Territory, that engages in any of the activities prohibited under this Clause 15. 

 The covenants herein contained apply not
only to the activities with which the Bottler may be directly concerned, but also to activities with which the Bottler may be indirectly concerned through ownership, control, management, partnership, agreement or otherwise, and whether located
within or outside of the Territory. 
  

	 	16.	It is understood and agreed among the parties that in the event that either: 

  

	 	(a)	a third party which is in the opinion of the Company directly or indirectly through ownership, control, management or otherwise, concerned with the manufacture, preparation, packaging, distribution or sale of any
product specified in Clause 15 hereof shall acquire or otherwise obtain control or any direct or indirect influence on the management of the Bottler; or 

  

	 	(b)	any person, firm or company having majority ownership or direct or indirect control of the Bottler or who is directly or indirectly controlled either by the Bottler or by any third party which has control or any direct
or indirect influence in the opinion of the Company on the management of the Bottler, shall engage in the preparation, packaging, distribution or sale of any products specified in Clause 15 hereof; 

  

					
		 		 	Page 7

 then the Company shall have the right to terminate this Agreement forthwith without liability
for damages unless the third party making such acquisition referred to in subclause (a) hereof or the person, firm or company referred to in subclause (b) hereof shall, on being notified in writing by the Company of its intention to
terminate as aforesaid, agrees to discontinue, and shall in fact discontinue, the manufacture, preparation, packaging, distribution or sale of such product(s) within a reasonable period not exceeding six (6) months from the date of
notification. 
  

	IV.	OBLIGATIONS OF BOTTLER RELATIVE TO THE PREPARATION AND PACKAGING OF THE BEVERAGE 

  

	 	17.     (a)	The Bottler covenants and agrees to use only the Concentrate in preparing the Syrup and the Syrup only for preparing and packaging the Beverage, in strict adherence to and compliance with the written instructions issued
to the Bottler from time to time by the Company. The Bottler further covenants and agrees that, in preparing, packaging and distributing the Beverage, the Bottler shall at all times conform to the standards, including quality, hygienic,
environmental and otherwise, established in writing from time to time by the Company and comply with all applicable legal requirements. 

  

	 	(b)	The Bottler, recognizing the importance of identifying the source of manufacture of the Beverage in the market, agrees to use identification codes on all packaging materials for the Beverage, including Approved
Containers and non-returnable cases. The Bottler further agrees to install, maintain and use the necessary machinery and equipment required for the application of such identification codes. The Company shall
provide the Bottler, from time to time, with necessary instructions in writing regarding the forms of the identification codes to be used by the Bottler in that connection, and the production and sales records to be maintained by the Bottler.

  

	 	(c)	In the event the Company determines or becomes aware of the existence of any quality or technical problems relating to the Beverage or Approved Containers in respect of the Beverage, the Company may require the Bottler
to take all necessary action to recall all of the Beverage or withdraw immediately any such Beverage from the market or the trade, as the case may be. The Company shall notify the Bottler by telephone, fax,
e-mail or any other form of immediate communication with written confirmed receipt, of the decision by the Company to require the Bottler to recall such Beverage or withdraw such Beverage from the market or
trade, and the Bottler shall, upon receipt of such notice, immediately cease distribution of such Beverage and take such other actions as may be required by the Company in connection with the recall of such Beverage or withdrawal of such Beverage
from the market or trade. 

  

	 	(d)	In the event the Bottler determines or becomes aware of the existence of quality or technical problems relating to the Beverage or Approved Containers in respect of the Beverage, then the Bottler shall immediately
notify the Company by telephone, fax, e-mail or any other form of immediate communication with written confirmed receipt. This notification shall include: (1) the identity and quantities of the Beverage
involved, including the specific Approved Containers, (2) coding data and (3) all other relevant data that will assist in tracing such Beverage. 

  

					
		 		 	Page 8

 The Bottler shall permit the Company, its officers, agents or designees, at all times to enter
and inspect the facilities, equipment and methods used by the Bottler, whether directly or incidentally, in or for the preparation, packaging, storage and handling of the Beverage to ascertain whether the Bottler is complying with the terms of this
Agreement, including, but not limited to Clauses 17 and 21. The Bottler also agrees to provide the Company with all the information regarding Bottler’s compliance with the terms of this Agreement, including, but not limited to, Clauses 17 and
21, as the Company may request from time to time. 
  

	 	18.	The Bottler shall submit to the Company, at the Bottler’s expense, samples of the Syrup, the Beverage and of materials used in the preparation of the Syrup and the Beverage, in accordance with instructions that the
Company may give from time to time. 

  

	 	19.     (a)	In the packaging, distribution and sale of the Beverage, the Bottler shall use only such Approved Containers and closures, cases, cartons, labels and other packaging materials approved from time to time by the Company,
and the Bottler shall purchase such items only from manufacturers who have been authorized in writing by the Company to manufacture the items to be used in connection with the Trade Marks and the Beverage. The Company shall use its best efforts to
approve two or more manufacturers of such items, it being understood that said approved manufacturers may be located within or outside of the Territory. 

  

	 	(b)	The Bottler shall inspect Approved Containers and closures, cases, cartons, labels and other packaging materials to be used in connection with the Beverage and shall use only those items which the Bottler has determined
comply with both the standards established by applicable laws in the Territory and the standards and specifications prescribed by the Company. The Bottler shall assume independent responsibility in connection with the use of such Approved
Containers, closures, cases, cartons, labels and other packaging materials which the Bottler has determined conform to such standards. 

  

	 	(c)	The Bottler shall maintain at all times a sufficient stock of Approved Containers, closures, cases, cartons, labels and other packaging materials to satisfy fully the demand for the Beverage in the Territory.

  

					
		 		 	Page 9

	 	 20.    (a)	The Bottler recognizes that increases in the demand for the Beverage, as well as changes in the Approved Containers, may from time to time require modifications or other changes in respect of its existing manufacturing,
packaging, delivery or vending equipment or require the purchase of additional manufacturing, packaging, delivery or vending equipment. The Bottler agrees to make such modifications to existing equipment and to purchase and install such additional
equipment as necessary with sufficient lead time to enable the introduction of new Approved Containers and the preparation and packaging of the Beverage in accordance with the continuing obligations of the Bottler to develop, stimulate and satisfy
fully every demand for the Beverage in the Territory. 

  

	 	(b)	In the event the Bottler uses refillable Approved Containers in the preparation, packaging, distribution and sale of the Beverage, the Bottler agrees to invest the necessary capital and to appropriate and expend such
funds as may be required from time to time to establish and maintain an adequate inventory of refillable Approved Containers. In order to ensure the continuing quality and appearance of said inventory of refillable Approved Containers, the Bottler
further agrees to replace all or part of the inventory of refillable Approved Containers as may be reasonably necessary and in accordance with the obligations of the Bottler pursuant to this Agreement. 

 

	 	(c)	The Bottler shall not use or permit the use of the Approved Containers, closures, cases, cartons, labels and other packaging materials referred to in this Agreement for any purpose, except in connection with the
Beverage and shall not refill or otherwise reuse any non-refillable Approved Containers that have been previously used. 

  

	 	 21.    (a)	The Bottler shall be solely responsible in carrying out its obligations herein for compliance with all laws, statutes, regulations, including Directives issued by the European Community,
by-laws and other legal requirements issued by government or local or other competent authorities and applicable in the Territory, and shall inform the Company forthwith of any provision thereof which would
prevent or limit in any way strict compliance by the Bottler with its obligations herein. 

  

	 	(b)	Without limiting the generality of the foregoing, the Bottler covenants and agrees to comply at all times with (i) all anti-bribery, environmental, health and safety laws, regulations, and other legal requirements
issued by government authorities and applicable in the Territory and (ii) the Company’s environmental management standards or program as issued from time to time in writing. 

  

					
		 		 	Page 10

	V.	CONDITIONS OF PURCHASE AND SALE 

  

	 	22.     (a)	The Company reserves the right, by giving written notice to the Bottler, to establish and to revise from time to time and at any time, in its sole discretion, the price of the Concentrate, the Authorized Supplier, the
supply point and alternate supply points for the Concentrate, the conditions of shipment and payment, and the currency or currencies acceptable to the Company or the Authorized Suppliers. 

 

	 	(b)	If the Bottler is unwilling to pay the revised price in respect of the Concentrate, then the Bottler shall so notify the Company in writing within thirty (30) days from receipt of the written notice from the
Company revising the aforesaid price. In such event, this Agreement shall terminate automatically without liability by any party for damages three (3) calendar months after receipt of the Bottler’s notification. 

 

	 	(c)	Any failure on the part of the Bottler to notify the Company in respect of the revised price of the Concentrate pursuant to subclause (b) hereof shall be deemed to be acceptance by the Bottler of the revised price.

  

	 	(d)	The Company reserves the right, to the extent permitted by the law applicable in the Territory, to establish and to revise, by giving written notice to the Bottler, maximum prices at which the Beverage in Approved
Containers may be sold by the Bottler to wholesalers and retailers and the maximum retail prices for the Beverage. It is recognized in this regard that the Bottler may sell the Beverage to wholesalers and retailers and authorize the retail sale of
the Beverage at prices which are lower than the maximum prices. The Bottler shall not, however, increase the maximum prices established or revised by the Company at which the Beverage in Approved Containers may be sold to wholesalers and retailers
nor authorize an increase in the maximum prices for the Beverage without the prior written consent of the Company. 

  

	 	(e)	The Bottler undertakes to collect from or charge to retail or wholesale outlets, as applicable, for each refillable Approved Container and each returnable case delivered to retail or wholesale outlets, such deposits as
the Company may determine from time to time by giving written notice to the Bottler, and to make all reasonably diligent efforts to recover all empty refillable Approved Containers and cases and, upon recovery, to refund or to credit the deposits
for said refillable Approved Containers and returnable cases returned undamaged and in good condition. 

  

	VI.	DURATION AND TERMINATION OF AGREEMENT 

  

	 	23.     (a)	This Agreement shall expire, without notice, on                     , unless it has been earlier terminated as provided
herein. It is recognized and agreed among the parties hereto that the Bottler shall have no right to claim a tacit renewal of this Agreement. 

  

					
		 		 	Page 11

	 	(b)	If the Bottler has fully complied with all the terms, covenants, conditions and stipulations of this Agreement throughout its term, and the Bottler is capable of the continued promotion, development and exploitation of
the full potential of the business of the preparation, packaging, distribution and sale of the Beverage, the Bottler may request an extension of this Agreement for an additional term of
                     (    ) years. The Bottler may request such extension by giving written notice to the Company at least six
(6) months but not more than twelve (12) months prior to the expiration date of this Agreement. The request by the Bottler for such extension shall be supported by such documentation as the Company may request, including documentation
relating to the Bottler’s compliance with the performance obligations under this Agreement and supporting the continued capability of the Bottler to develop, stimulate and satisfy fully the demand for the Beverage within the Territory. If the
Bottler has, in the sole discretion of the Company, satisfied the conditions for the extension of this Agreement, then the Company may, by written notice, agree to extend this Agreement for such additional term or such lesser period as the Company
may determine. 

  

	 	(c)	At the expiration of any such additional term, this Agreement shall expire finally without further notice, and the Bottler shall have no right to claim a tacit renewal of this Agreement. 

 

	 	24.     (a)	This Agreement may be terminated by the Company or the Bottler forthwith and without liability for damages by written notice given by the party entitled to terminate to the other party: 

 

	 	(1)	if the Company, the Authorized Suppliers or the Bottler cannot legally obtain foreign exchange to remit abroad in payment of imports of the Concentrate or the ingredients or materials necessary for the manufacture of
the Concentrate, the Syrup or the Beverage; or 

  

	 	(2)	if any part of this Agreement ceases to be in conformity with the laws or regulations applicable in the Territory and, as a result thereof, or as a result of any other laws affecting this Agreement, any one of the
material stipulations herein cannot be legally performed or the Syrup cannot be prepared, or the Beverage cannot be prepared or sold in accordance with the instructions issued by the Company pursuant to Clause 17 above, or if the Concentrate cannot
be manufactured or sold in accordance with the Company’s formula or the standards prescribed by it. 

  

	 	(b)	This Agreement may be terminated forthwith by the Company without liability for damages: 

  

	 	(1)	 if the Bottler becomes insolvent, or if a petition in bankruptcy is filed against or on behalf of the Bottler
which is not stayed or 

  

					
		 		 	Page 12

	 	
dismissed within one hundred and twenty (120) days, or if the Bottler passes a resolution for winding up, or if a winding up or judicial management order is made against the Bottler, or if a
receiver is appointed to manage the business of the Bottler, or if the Bottler enters into any judicial or voluntary scheme of composition with its creditors or concludes any similar arrangements with them or makes an assignment for the benefit of
creditors; or 

  

	 	(2)	in the event of the Bottler’s dissolution, nationalization or expropriation, or in the event of the confiscation of the production or distribution assets of the Bottler. 

 

	 	25.     (a)	This Agreement may also be terminated by the Company or the Bottler without liability for damages if the other party fails to observe any one or more of the terms, covenants or conditions of this Agreement, and fails to
remedy such default(s) within sixty (60) days after such party has been given written notice of such default(s). 

  

	 	(b)	In addition to all other remedies to which the Company may be entitled hereunder, if at any time the Bottler fails to follow the instructions or to maintain the standards prescribed by the Company or required by
applicable laws in the Territory for the preparation and packaging of the Syrup or the Beverage, the Company shall have the right to prohibit the production of the Syrup or the Beverage until the default has been corrected to the Company’s
satisfaction, and the Company may demand the suspension of distribution and delivery of the Beverage and further demand the recall or withdrawal from the market or trade, at the Bottler’s expense, of the Beverage not in conformity with or not
manufactured in conformity with such instructions, standards or requirements, and the Bottler shall promptly comply with such prohibition or demand. During the period of such prohibition of production, the Company shall be entitled to suspend
deliveries of the Concentrate to the Bottler and to supply the Beverage or to arrange for others to supply the Beverage in the Territory. No prohibition or demand shall be deemed a waiver of the rights of the Company to terminate this Agreement
pursuant to this Clause 25. 

  

	 	26.	Upon the expiration or earlier termination of this Agreement: 

  

	 	(a)	the Bottler shall not thereafter prepare, package, distribute, or sell the Beverage or make any use of the Trade Marks, Approved Containers, closures, cases, cartons, labels, other packaging material or advertising,
marketing or promotional material used or which are intended for use by the Bottler solely in connection with the preparation, packaging, distribution and sale of the Beverage; 

 

	 	(b)	 the Bottler shall forthwith eliminate all references to the Company, the Beverage and the Trade Marks from the
premises, delivery vehicles, vending machines, coolers and other equipment of the Bottler and from all business stationery and all written, graphic, electromagnetic, digital or other

  

					
		 		 	Page 13

	 	
advertising, marketing or promotional material used or maintained by the Bottler, and the Bottler shall not thereafter hold forth in any manner whatsoever that the Bottler has any connection with
the Company, the Beverage or the Trade Marks; 

  

	 	(c)	the Bottler shall forthwith deliver to the Company or a third party, in accordance with such instructions as the Company shall give, all of the Concentrate, Beverage in Approved Containers, usable Approved Containers
bearing the Trade Marks or any of them, closures, cases, cartons, labels and other packaging materials bearing the Trade Marks and advertising material for the Beverage still in the Bottler’s possession or under its control, and the Company
shall, upon delivery thereof pursuant to such instructions, pay to the Bottler a sum equal to the reasonable market value of such supplies or materials, provided that the Company will accept and pay for only such supplies or materials as are in first-class and usable condition; and provided further that all Approved Containers, closures, cases, cartons, labels and other packaging materials and advertising materials bearing the name of the Bottler and any
such supplies and materials which are unfit for use according to the Company’s standards shall be destroyed by the Bottler without cost to the Company; and provided further that, if this Agreement is terminated in accordance with the provisions
of Clauses 16, 22(b), 24(a), 25 or 27 or as a result of any of the contingencies provided in Clause 30 (including termination by operation of law), or if the Agreement is terminated by the Bottler for any reason other than in accordance with or as a
result of the operation of Clauses 22(b) or 25, the Company shall have the option, but no obligation, to purchase from the Bottler the supplies and materials referred to above; and 

 

	 	(d)	all rights and obligations hereunder, whether specifically set out or whether accrued or accruing by use, conduct or otherwise, shall expire, cease and end, excepting all provisions concerning the obligations of the
Bottler as set forth in Clauses 11(a)(2) and (a)(3) and 12, 13, 14, 26, 31, 32, 33(a), 33(c) and 33(d), all of which shall continue in full force and effect, provided always that this provision shall not affect any rights the Company may have
against the Bottler in respect of any claim for nonpayment of any debt or account owed by the Bottler to the Company or its Authorized Suppliers. 

  

	VII.	OWNERSHIP AND CONTROL OF THE BOTTLER 

  

	 	27.	 It is recognized and acknowledged among the parties hereto that the Company has a vested and legitimate interest
in maintaining, promoting and safeguarding the overall performance, efficiency and integrity of the Company’s international bottling, distribution and sales system. It is further recognized and acknowledged among the parties hereto that this
Agreement has been entered into by the Company intuitu personae and in reliance upon the identity, character and integrity of the owners, controlling parties and managers of the Bottler, and the Bottler warrants having made to the Company prior to
the execution hereof a full and 

  

					
		 		 	Page 14

	 	
complete disclosure of the owners and of any third parties having a right to, or power of, control or management of the Bottler. It is therefore agreed between the parties hereto that
notwithstanding the provisions of Clause 16 or any other provision of this Clause 27, in the event of any change, due to any cause, of the real persons or legal entities having direct or indirect ownership or control of the Bottler, including any
changes of the share-owner composition of such entities, the Company, in its sole discretion, may terminate this Agreement forthwith and without liability for damages. The Bottler, therefore, covenants and
agrees: 

  

	 	(a)	not to assign, transfer, pledge or in any way encumber this Agreement or any interest herein or rights hereunder, in whole or in part, to any third party or parties without the prior written consent of the Company;

  

	 	(b)	not to delegate performance of this Agreement, in whole or in part, to any third party or parties without the prior written consent of the Company; 

 

	 	(c)	to notify the Company promptly in the event of or upon obtaining knowledge of any third party action which may or will result in any change in the ownership or control of the Bottler; 

 

	 	(d)	to make available from time to time and at the request of the Company complete records of current ownership of the Bottler and full information concerning any third party or parties by whom it is controlled, directly or
indirectly; 

  

	 	(e)	to the extent the Bottler has any legal control over changes in the ownership or control of the Bottler, not to initiate or implement, consent to or acquiesce in any such change without the prior written consent of the
Company; and 

  

	 	(f)	if the Bottler is organized as a partnership, not to change the composition of such partnership by the inclusion of any new partners or the release of existing partners without the prior written consent of the Company.

 In addition to the foregoing provisions of this Clause 27, if a proposed change in ownership or control of the Bottler
involves a direct or indirect transfer to or acquisition of ownership or control of the Bottler, in whole or in part, by a person or entity authorized by the Company to manufacture, sell, distribute or otherwise deal in any beverage products and/or
any trade marks of the Company (the “Acquiror Bottler”), the Company may request any and all information it considers relevant from both the Bottler and the Acquiror Bottler in order to make its determination as to whether to consent to
such change. In any such circumstances, the parties hereto, recognizing and acknowledging the vested and legitimate interest of the Company in maintaining, promoting and safeguarding the overall performance, efficiency and integrity of the
Company’s international bottling, distribution and sales system, expressly agree that the Company may consider all and any factors, and apply any criteria that it considers relevant in making such determination. 

  

					
		 		 	Page 15

 It is further recognized and agreed among the parties hereto that the Company, in its sole
discretion, may withhold consent to any proposed change in ownership or other transaction contemplated in this Clause 27, or may consent subject to such conditions as the Company, in its sole discretion, may determine. The parties hereto expressly
stipulate and agree that any violation by the Bottler of the foregoing covenants contained in this Clause 27 shall entitle the Company to terminate this Agreement forthwith without liability for damages; and, furthermore, in view of the personal
nature of this Agreement, that the Company shall have the right to terminate this Agreement without liability for damages if any other third party or parties should obtain any direct or indirect interest in the ownership or control of the Bottler,
even when the Bottler had no means to prevent such a change, if, in the opinion of the Company, such change either enables such third party or parties to exercise a decisive influence over the management of the Bottler or materially alters the
ability of the Bottler to comply fully with the terms, obligations and conditions of this Agreement. 
  

	 	28.	The Bottler shall, prior to the issue, offer, sale, transfer, trade or exchange of any of its shares of stock or other evidence of ownership, its bonds, debentures or other evidence of indebtedness, or the promotion of
the sale of the above, or stimulation or solicitation of the purchase or an offer to sell thereof, obtain the written consent of the Company whenever the Bottler uses in this connection the name of the Company or the Trade Marks or any description
of the business relationship with the Company in any prospectus, advertisement or other sales efforts. The Bottler shall not use the name of the Company or the Trade Marks or any description of the business relationship with the Company in any
prospectus or advertisement used in connection with the Bottler’s acquisition of any shares or other evidence of ownership in a third party without the Company’s prior written consent. 

 

	VIII.	GENERAL PROVISIONS: 

  

	 	29.	The Company may assign any of its rights and delegate all or any of its duties or obligations under this Agreement to one or more of its subsidiaries or related companies provided, however, that any such delegation
shall not relieve the Company from any of its contractual obligations under this Agreement. In addition, the Company, in its sole discretion, may through written notice to the Bottler appoint a third party as its representative to ensure that the
Bottler carries out its obligations under this Agreement, with full powers to oversee the Bottler’s performance and to require from the Bottler its compliance with all the terms and conditions of this Agreement. 

 

	 	30.	Neither the Company nor the Bottler shall be liable for failure to perform any of their respective obligations hereunder when such failure is caused by or results from: 

 

	 	(a)	strike, blacklisting, boycott or sanctions imposed by a sovereign nation or supra-national organization of sovereign nations, however incurred; or 

  

					
		 		 	Page 16

	 	(b)	act of God, force majeure, public enemies, authority of law and/or legislative or administrative measures (including the withdrawal of any government authorization required by any of the parties to carry out the terms
of this Agreement), embargo, quarantine, riot, insurrection, a declared or undeclared war, state of war or belligerency or hazard or danger incident thereto; or 

  

	 	(c)	any other cause whatsoever beyond their respective control. 

 In the event the Bottler is
unable to perform its obligations as a consequence of any of the contingencies set forth in this Clause 30, and for the duration of such inability, the Company and Authorized Suppliers shall be relieved of their respective obligations under Clauses
2 and 5; and provided that, if any such failure by any party shall persist for a period of six (6) months or more, any of the parties hereto may terminate this Agreement without liability for damages. 

 

	 	31.     (a)	The Coca-Cola Company reserves the sole and exclusive right to institute any civil, administrative or criminal proceedings or actions, and generally to take or seek any available
legal remedy it deems desirable, for the protection of its reputation, Trade Marks, and other intellectual property rights, as well as for the protection of the Concentrate, the Syrup and the Beverage, and to defend any action affecting these
matters. At the request of The Coca-Cola Company, the Bottler will render assistance in any such action. The Bottler shall not have any claim against the Company as a result of such proceedings or action or
for any failure to institute or defend such proceedings or action. The Bottler shall promptly notify the Company of any litigation or proceedings instituted or threatened affecting these matters. The Bottler shall not institute any legal or
administrative proceedings against any third party which may affect the interests of the Company without the prior written consent of the Company. 

  

	 	(b)	The Coca-Cola Company has the sole and exclusive right and responsibility to initiate and defend all proceedings and actions relating to the Trade Marks. The Coca-Cola Company may initiate or defend any such proceedings or actions in its own name or require the Bottler to institute or defend such proceedings or actions either in its own name or in the joint names of the
Bottler and The Coca-Cola Company. 

  

	 	32.     (a)	The Bottler agrees to consult with the Company on all product liability claims, proceedings or actions brought against the Bottler in connection with the Beverage or Approved Containers and to take such action with
respect to the defense of any such claim or lawsuit as the Company may reasonably request in order to protect the interests of the Company in the Beverage, the Approved Containers or the goodwill associated with the Trade Marks. 

 

	 	(b)	 The Bottler shall indemnify and hold harmless the Company, its affiliates and their respective officers,
directors and employees from and against all costs, expenses, damages, claims, obligations and liabilities whatsoever 

  

					
		 		 	Page 17

	 	
arising from facts or circumstances not attributable to the Company including, but not limited to, all costs and expenses incurred in settling or compromising any of the same arising out of the
preparation, packaging, distribution, sale or promotion of the Beverage by the Bottler, including, but not limited to, all costs arising out of the acts or defaults, whether negligent or not, of the Bottler, the Bottler’s distributors,
suppliers and wholesalers. 

  

	 	(c)	The Bottler shall obtain and maintain a policy of insurance with insurance carriers satisfactory to the Company giving full and comprehensive coverage both as to amount and risks covered in respect of matters referred
to in subclause (b) above (including the indemnity contained therein) and shall on request produce evidence satisfactory to the Company of the existence of such insurance. Compliance with this Clause 32(c) shall not limit or relieve the Bottler
from its obligations under Clause 32(b) hereof. 

  

	 	33.	The Bottler covenants and agrees: 

  

	 	(a)	that it will make no representations or disclosures to public or government authorities or to any other third party, relating to the Concentrate, the Syrup or the Beverage without the prior written consent of the
Company; 

  

	 	(b)	in the event that the Bottler is publicly listed or traded, it will disclose to the Company any financial or other information relating to the performance or prospects of the Bottler at the same time as the Bottler is
required to disclose such information pursuant to the regulations of the stock exchange or the securities or corporations law applicable to the Bottler; 

  

	 	(c)	that it will at all times, both during the continuance and after termination of this Agreement, keep strictly confidential all secret and confidential information including, without limiting the generality of the
foregoing, mixing instructions and techniques, sales, marketing and distribution information, projects and plans, relating to the subject matter of this Agreement, which the Bottler may receive from the Company, or in any other manner, and to ensure
that such information shall be made known only to those officers, directors and employees bound by reasonable provisions incorporating the secrecy obligations set out in this Clause; and 

 

	 	(d)	that upon the expiration or earlier termination of this Agreement, it will forthwith hand over to the Company or to whomever the Company may direct all written or graphic, electromagnetic, computerized, digital or other
materials comprising or containing any information subject to the obligation of confidentiality hereunder. 

  

	 	34.	 The Company and the Bottler recognize that incidents may arise which can threaten the reputation and business of
the Bottler and/or negatively affect the good name, reputation and image of The Coca-Cola Company and the Trade Marks. In order to address such incidents, including but not limited to any questions of quality
of the Beverage that may occur, the Bottler will designate and organize an 

  

					
		 		 	Page 18

	 	
incident management team and inform the Company of the members of such team. The Bottler further agrees to cooperate fully with the Company and such third parties as the Company may designate and
coordinate all efforts to address and resolve any such incident consistent with procedures for crisis management that may be issued to the Bottler by the Company from time to time. 

 

	 	35.	In the event of any provisions of this Agreement being or becoming legally ineffective or invalid, the validity or effect of the remaining provisions of this Agreement shall not be affected; provided that the invalidity
or ineffectiveness of the said provisions shall not prevent or unduly hamper performance hereunder or prejudice the ownership or validity of the Trade Marks. The right to terminate in accordance with Clause 24 (a)(2) is not affected hereby.

  

	 	36.     (a)	As to all matters and things herein mentioned, this Agreement, as may be amended or supplemented in writing from time to time, shall constitute the only agreement among the Company and the Bottler. All prior agreements
of any kind whatsoever among the parties relating to the subject matter are cancelled hereby; provided, however, that any written representations made by the Bottler upon which the Company relied in entering into this Agreement shall remain binding
upon the Bottler. 

  

	 	(b)	Any waiver or modification of, or alteration or addition to, this Agreement or any of its provisions, shall not be binding upon the Company or the Bottler unless same shall be executed by duly authorized representatives
of the Company and the Bottler. 

  

	 	(c)	All written notices given pursuant to this Agreement shall be by courier, telefax, hand or registered (air) mail and shall be deemed to be given on the date such notice is dispatched, such hand delivery is effected, or
such registered letter is mailed. Such written notices shall be addressed to the last known address of the party concerned. Each party shall promptly advise the other parties of any change in its address. 

 

	 	37.	Failure of the Company to exercise promptly any right herein granted, or to require strict performance of any obligation undertaken herein by the Bottler, shall not be deemed to be a waiver of such right or of the right
to demand subsequent performance of any and all obligations herein undertaken by the Bottler. 

  

	 	38.	The Bottler is an independent contractor and is not an agent of, or a partner or joint venturer with, the Company. The Bottler agrees that it will neither represent, nor allow itself to be held out as an agent of, or
partner or joint venturer with the Company. 

  

	 	39.	The headings herein are solely for the convenience of the parties and shall not affect the interpretation of this Agreement. 

  

	 	40.	This Agreement shall be interpreted, construed and governed by and in accordance with the laws of                     ,
without giving effect to any applicable principles of choice or conflict of laws. 

  

					
		 		 	Page 19

 IN WITNESS WHEREOF, The Coca-Cola Company and The Coca-Cola Export Corporation in Atlanta, Georgia, United States of America, and the Bottler in                     
have caused these presents to be executed in triplicate by the duly authorized person or persons in their behalf on the dates indicated below. 
  

									
	THE COCA-COLA COMPANY	 		 	[BOTTLER]
					
	By:	 	  
	 		 	By:	 	  

		 	Authorized Representative	 		 		 	Authorized Representative
					
	Date:	 	  
	 		 	Date:	 	  

				
	THE COCA-COLA EXPORT CORPORATION	 		 		 	
					
	By:	 	  
	 		 		 	
		 	Authorized Representative	 		 		 	
					
	Date:	 	  
	 		 		 	

  

					
		 		 	Page 20EX-10.1

 Exhibit 10.1 

[PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIALITY UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT THAT HAVE BEEN OMITTED ARE MARKED WITH “[***].” A COPY OF THIS EXHIBIT WITH ALL SECTIONS INTACT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 FDBU-BMT Commercial Supply Agreement 

COMMERCIAL SUPPLY AGREEMENT 
 This
Commercial Supply Agreement dated March 29, 2016 (this “Agreement”) between BioMimetic Therapeutics, LLC (“Sponsor”), a Delaware limited liability company, with offices 389 Nichol Mill Lane, Franklin, TN 37067
and FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Delaware corporation (“Fujifilm”), having its principal place of business at 101 J. Morris Commons Lane, Morrisville, NC 27560, (each a “Party”, collectively,
the “Parties”). 
 WHEREAS, Sponsor and Fujifilm entered into a Master Bioprocessing Services Agreement dated [***] that was or may be
subsequently amended with change orders (“MBSA”), pursuant to which Fujifilm agreed to perform certain process development services including process validation and Conformance Campaign (as defined below) with respect to the
material known as rhPDGF-BB on behalf of Sponsor; 
 WHEREAS, Sponsor wants Fujifilm to Manufacture (as defined below) in accordance with the terms of this
Agreement the Drug Substance (as defined below), for routine commercial supply of the Drug Product (as “Drug Product” is defined below); and 

WHEREAS, Fujifilm wants to Manufacture the Drug Substance. 

Now, therefore, in consideration of the above statements, which form part of this Agreement, and other good and valuable consideration, the sufficiency and
receipt of which are hereby acknowledged, the Parties hereto agree as follows: 
 Definitions: 

“Affiliate” shall mean in relation to either Party, any corporation, association or other business entity which directly or indirectly
controls, is controlled by or is under common control with such Party and “control” shall mean the legal power to direct or cause the direction of the general management and policies of such entity whether through the ownership of at least
50% of voting securities or capital stock of such business entity or any other comparable equity or ownership interest with respect to a business entity other than a corporation. 

“Agreement” shall have the meaning set forth in the preamble. 

“Annual Program Fee” shall mean the annual fee paid for Process Surveillance and Regulatory Support as specified in Sections 3(b) and 3(c)
and disposal fees, as set forth in Attachment 1. The Annual Program Fee does not include non-routine activities, such as pre-approval inspections, mock inspections and other efforts needed to prepare for pre-approval inspections. 

“Assumptions” shall have the meaning set forth in Section 11(a). 

“Batch” shall mean a Drug Substance Batch. 

“Batch Packet” shall mean the package of relevant documentation, including, but not limited to, production records, in-process and release
testing, and QA lot release documents, to be transferred to Sponsor in relation to a Drug Substance Batch as detailed in Attachment A to the Quality Agreement. 

  

			
	CONFIDENTIAL	  	1
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 “Batch Price” shall mean the Manufacturing Price plus the price of Process Consumables
Category A and B used in the Manufacture of a Drug Substance Batch. 
 “Binding Order” shall mean a non-cancellable order(s) of a specified
number of Batches to be delivered to Sponsor (and Sponsor’s Commercial Partner, if applicable) by Fujifilm in accordance with Section 16, which order shall be submitted to Fujifilm according to the process specified in Section 4. 

“Biologics License Application” or “BLA” shall mean Sponsor’s request for permission to introduce, or deliver for introduction
a biologic product into commerce under 21 CFR 601.2, 21 CFR 211 and equivalent non-US regulations. Sponsor is the applicant and subsequent Holder of the Registration Documents (i.e. BLA or equivalent non-US regulatory documents) for Drug Substance.

 “Campaign” shall mean the Manufacture of an Intermediate Batch or Drug Substance Batch or a series of Intermediate Batches or Drug
Substance Batches. 
 “Campaign Fee” shall mean together the Campaign Report Fee and the Resin Price. 

“Campaign Report Fee” shall mean the price of campaign summary reports specified in Attachment 1 that is invoiced per each campaign as part
of the Campaign Fee. 
 “cGMP” shall mean current Good Manufacturing Practice pursuant to (a) the U.S. Federal Food, Drug and
Cosmetics Act as amended (21 USC 301 et seq), (b) U.S. regulations in Title 21 of the US Code of Federal Regulations Parts 210, 211, 600 and 610, (c) the EC Guide to Good Manufacturing Practices for Medicinal Products v.4, including
relevant sections of DIR 2003/94/EC, and (d) International Conference of Harmonization (ICH) Guidance for Industry Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. 

“Change Order” shall have the meaning set forth in Section 11(b). 

“Claim” shall have the meaning set forth in Section 19. 

“Confidential Information” shall have the meaning set forth in Section 12(d). 

“Conformance Campaign” shall mean the manufacturing campaign at Fujifilm to be performed in 2016 under the MBSA and the associated Scope of
Work #1 under the MBSA. 
 “Downstream Campaign” shall mean a Manufacturing campaign to produce Drug Substance from Intermediate. 

“Drug Product” shall mean the filled and finished final dosage form of Drug Substance together with other active or inactive ingredients
intended for commercial or clinical use. 
 “Drug Substance” shall mean [***] derived recombinant human platelet derived growth factor
B-homodimer, rhPDGF-BB purified from Intermediate. 
 “Drug Substance Batch” shall mean Drug Substance derived from [***] fermentation runs
of Intermediate at [***] working volume scale producing [***] Intermediate Batches resulting in [***] of purified Drug Substance. 

  

			
	CONFIDENTIAL	  	2
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 “Drug Substance Batch Price” shall mean the portion of the Batch Price allocated to the
Manufacturing of the Drug Substance Batch from Intermediate. The price of one (1) Drug Substance Batch shall be [***] of the Batch Price. 

“Drug Substance Manufacturing Campaign” shall mean a manufacturing campaign to produce Drug Substance from Intermediate 

“Drug Substance Invention” shall have the meaning set forth in Section 13(a). 

“Drug Substance Specifications” shall mean the specifications agreed by the parties for the Drug Substance pursuant to the Quality Agreement
and attached to the Quality Agreement. 
 “Extension Term” shall have the meaning set forth in Section 24(a). 

“Facility” or “Facilities” shall mean, collectively or individually, the GMP Facility, Fujifilm’s process development
laboratories and Fujifilm’s administrative building located at 101 J. Morris Commons Lane, Morrisville, North Carolina 27560. 
 “FDA”
shall mean the United Stated Food and Drug Administration. 
 “Force Majeure” shall mean any cause beyond the reasonable control of the
non-performing party which for the avoidance of doubt and without prejudice to the generality of the foregoing shall include governmental actions, war, riots, terrorism, civil commotion, fire, flood, epidemic, labour disputes (excluding labour
disputes involving the work force or any part thereof of the party in question), restraints or delays affecting shipping or carriers, currency restrictions, and act of God, but shall not include failure of Drug Product in clinical trials or failure
of Drug Product to gain regulatory approval or the negligence or intentional misconduct of the non-performing party. 
 “[***]
Eluate” shall mean the Intermediate Batch produced from [***] fermentations followed by capture on a [***] column and eluation from that column. 

“Fujifilm Confidential Information” shall have the meaning set forth in Section 12(b). 

“Fujifilm Factor” shall mean (i) [***], or (ii) [***], (iii) [***], or (iv) [***] specified in process documentation.

 “Fujifilm Group” shall have the meaning set forth in Section 19(b). 

“GMP Facility” shall mean Fujifilm’s manufacturing plant located at 6051 George Watts Hill Drive, Durham, North Carolina 27709. 

“Indemnified Party” shall have the meaning set forth in Section 19(c). 

“Indemnity Claim” shall have the meaning set forth in Section 19(c). 

“Initial Term” shall have the meaning set forth in Section 24(a). 

“Intermediate” shall mean [***] eluate Manufactured in the GMP Facility. 

  

			
	CONFIDENTIAL	  	3
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 “Intermediate Batch” shall mean [***] eluate Manufactured in the GMP Facility from [***]
working volume fermentations. [***] Intermediate Batches are used to Manufacture [***] Drug Substance Batch. 
 “Intermediate Batch Price”
shall mean the portion of the Batch Price allocated to the Manufacturing of the Intermediate Batches used in the Manufacture of such Drug Substance Batch. The price of one (1) Intermediate Batch shall be [***] of the Batch Price. 

“Intermediate Manufacturing Campaign” shall mean a manufacturing campaign to produce Intermediate 

“Joint Steering Committee” shall have the meaning set forth in Section 26(a). 

“Key Manufacturing Assumptions” shall have the meaning set forth in Section 11(a). 

“Loss” shall have the meaning set forth in Section 19(a). 

“Manufacture” shall mean the manufacture of Intermediate and Drug Substance by Fujifilm and related activities, such as quality assurance,
quality control and testing. 
 “Manufacturing Price” shall mean the price for Manufacture of a Drug Substance, as set forth in Attachment
1. 
 “Maximum Annual Order” shall mean the maximum number of Batches that Fujifilm shall be obligated to Manufacture in a calendar year
for Sponsor and its Commercial Partners, as further defined in Section 4(b). 
 “Minimum Annual Order” shall mean the minimum number
of Batches that Sponsor and its Commercial Partners together shall be obligated to purchase and Fujifilm shall be obligated to Manufacture in a calendar year pursuant to Binding Orders, as determined according to Section 4(b). 

“Minimum Order Quantity” shall mean the minimum number of Batches that Sponsor and its Commercial Partners shall be obligated to purchase
under a Binding Order and Fujifilm shall be obligated to Manufacture pursuant to a Binding Order(s) from Sponsor and its Commercial Partners, as determined according to Section 4(b). 

“Modification” shall have the meaning set forth in Section 11(b). 

“[***] Batch” shall mean a Drug Substance batch which: (i) has [***] produced in accordance with [***]; (ii) does [***] the Drug
Substance [***]; or (iii) does [***] the requirements outlined in the [***] in writing by [***]. 
 “Party” or “Parties”
shall have the meaning set forth in the preamble. 
 “Process Consumables” shall mean materials consumed during the Manufacture of
Intermediate and Drug Substance. For purpose of this Agreement, this definition includes, but is not limited to, [***]. 
 “Process Consumables
Category A” shall mean Process Consumables which are part of Fujifilm’s common stock. 

  

			
	CONFIDENTIAL	  	4
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 “Process Consumables Category B” shall mean Process Consumables which can only be sourced
from one vendor, the list of which is included in Attachment 2. 
 “Process Consumables Category C” shall mean resins, the list of which is
included in Agreement 2. 
 “Process Consumables Price” shall mean the price for Process Consumables Category A and Process Consumables
Category B used in the Manufacture of such Drug Substance Batch including a [***] fee for [***] of such Process Consumables. 
 “Process
Invention” shall have the meaning set forth in Section 13(a). 
 “Program” shall mean the Manufacturing services to be
performed under this Agreement. 
 “Purchase Order” shall mean a purchase order(s) issued by Sponsor and/or Sponsor’s Commercial
Partner against then current Drug Substance Binding Order 
 “Quality Agreement” shall mean the commercial quality agreement that Parties
shall enter into no later than [***], which may be amended from time to time, and which shall contain essentially the same terms, when applicable, as the Quality Agreement signed on [***]. 

“Registration Documents” shall mean any and all Regulatory Authority approvals necessary for the distribution, import, storage or handling of
the Drug Product and the manufacturing, import, marketing, distribution and sale of the Drug Product as labeled, packaged and presented for sale to the health care trade. 

“Regulatory Authority” shall mean any national, regional, state or local regulatory agency, department, bureau, commission, council or other
governmental entity with authority over the Manufacture, production, use or storage, transport, clinical testing, marketing, pricing or sale of Drug Substance in the United States, Canada, European Union, and Australia, including FDA, or any
successor agency or authority thereto, and the European Medicines Agency, or any successor agency or authority thereto or any such foreign regulatory body that has adopted equivalent regulations for the Manufacture, production, use, storage,
transport, clinical testing, marketing, pricing or sale of Drug Substance as the United States and/or the European Union. This definition may be expanded to other regulatory authorities upon mutual written agreement. 

“Reservation Fee” shall have the meaning set forth in Section 9(a). 

“Resin Price” shall mean the price for Process Consumables Category C including a [***] fee for handling, storage and testing of such Process
Consumables. 
 “Safety Stock” shall have the meaning set forth in Section 8(b). 

“Specifications” shall mean the specifications agreed by the parties for the Product pursuant to the Quality Agreement. 

“Sponsor” shall have the meaning set forth in the preamble. 

“Sponsor’s Commercial Partners” shall have the meaning set forth in Section 2. Attachment 4 lists Sponsor’s Commercial
Partners. 
 “Sponsor’s Confidential Information” shall have the meaning set forth in Section 12(a). 

  

			
	CONFIDENTIAL	  	5
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 “Sponsor Deliverables” shall mean the reference standard materials and Starting Material

 “Starting Material” shall mean the vials of [***] working cell banks. 

“Upstream Campaign” shall mean a Manufacturing Campaign to produce Intermediate. 

Section 1 
 Relation to Quality Agreement 

Terms defined in this Agreement shall have the same meaning when used in the Quality Agreement. In the event of any conflict between this Agreement and the
Quality Agreement, the terms of this Agreement shall have precedence, except with respect to matters of quality and regulatory, in which case the terms of the Quality Agreement shall govern. 

Section 2 
 Biologic License Application and
Sponsor’s Commercial Partners 
 The Parties acknowledge and agree that Sponsor intends to be the Registration Document (i.e. BLA, EMA, etc.)
holder for Drug Product in all territories where such Drug Product will be sold by Sponsor, Sponsor’s Commercial Partners, and Other Recipients of Drug Substance (as defined below and listed in Attachment 4.) Furthermore, the Parties
acknowledge that Sponsor is in contractual agreements, or may enter into contractual agreements during the Term, with third parties, including without limitation, [***] and [***] (collectively, “Recipients of Drug Substance”), as
listed in Attachment 4 that can be amended from time to time by mutual agreement of Parties, that may introduce Drug Product into commerce under Sponsor’s Registration Documents (i.e. BLA, EMA, etc.). If agreed in writing by Sponsor by amending
Attachment 4, Fujifilm may enter into separate commercial supply agreements with selected Recipients of Drug Substance designated in Attachment 4 as Sponsor’s Commercial Partners (“Sponsor’s Commercial Partners”), subject
to Section 3 e) below in all respects. 
 Section 3 

Manufacture of Product 
  

	 	a)	Manufacture of Drug Substance. Fujifilm will Manufacture the Drug Substance under Sponsor’s BLA exclusively for Sponsor and Sponsor’s Commercial Partners at the GMP Facility, based on Binding Orders
submitted by Sponsor, in accordance with the terms and conditions of this Agreement, the Quality Agreement and cGMP. 

  

	 	b)	Process Surveillance. Fujifilm will perform process surveillance on all Batches Manufactured under this Agreement, which will include the surveillance listed below in addition to any surveillance detailed in the
Quality Agreement: 

  

	 	I.	Trending process yield and release testing data in accordance with the mutually agreed process surveillance plan, including per [***]; 

 

	 	II.	Statistical analysis of surveillance parameters at the end of each [***] once a minimum of [***] are available; 

  

	 	III.	Preparation of surveillance parameter data report after [***] of each [***]; and 

  

			
	CONFIDENTIAL	  	6
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	IV.	Trend analysis across all [***] in the previous year in support of the Annual Planning Meeting. 

  

	 	c)	Regulatory Support. Fujifilm will provide routine regulatory support to Sponsor for the Program directly related to Drug Substance at Sponsor’s request that will include: 

 

	 	I.	Review and comment on the initial and the routine [***]; 

  

	 	II.	Support of [***] and responses to any [***]; 

  

	 	III.	Updates to [***]; and 

  

	 	IV.	Site [***]. 

 Any additional regulatory support, including without limitation support of any
regulatory submissions outside of the United States, [***], which exceeds reasonable expectations of the Parties established upon Agreement execution, will be mutually agreed upon by the parties and provided by Fujifilm based on a Change Order or
separate agreement. 
  

	 	d)	Sponsor Obligations. Sponsor shall: 

  

	 	I.	Perform its obligations as set forth in this Agreement and the Quality Agreement. 

  

	 	II.	Support and cooperate with the execution of the Program and each Binding Order. 

  

	 	III.	Not engage in any negligent act or omission, which may reasonably be expected to prevent or delay the successful execution of the Program. 

 

	 	e)	[***]. 

 Section 4 

Ordering; Annual Planning Meetings; Scheduling 
  

	 	a)	Intermediate Safety Stock. Fujifilm shall establish and carry a Safety Stock of Intermediate sufficient to Manufacture one (1) Batch of Drug Substance. Sponsor may specify higher level of Intermediate Safety
Stock. The safety stock of Intermediate shall be established during the [***]. The Intermediate from the safety stock shall be utilized in the [***] Drug Substance Manufacturing Campaign and shall be continuously replenished with new Batches from
Intermediate Manufacturing Campaigns. The cost of Intermediate Safety Stock shall be [***]. A [***] for establishing or increasing Intermediate Safety Stock shall be delivered to Fujifilm by Sponsor no later than [***] of the year preceding the
establishment or increase in Intermediate Safety Stock. 

  

	 	b)	Minimum and Maximum Annual Orders 

  

	 	I.	Fujifilm, Sponsor, and its Commercial Partners shall [***] on a Minimum Annual Order and a Maximum Annual Order during a calendar year. The Minimum and the Maximum Annual Orders shall be [***] during Annual Planning
Meetings to ensure they meet then current forecast and if adjustments are required, new limits for Minimum Annual Orders and/or Maximum Annual Orders, as applicable, shall be [***] and recorded in an Agreement addendum. 

 

	 	II.	The Minimum Order Quantity shall be [***] Batches 

  

	 	III.	The initial Minimum Annual Order shall be [***] Batches 

  

	 	IV.	The initial Maximum Annual Order shall be [***] Batches 

  

			
	CONFIDENTIAL	  	7
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	c)	Manufacturing Campaigns in 2017 and 2018. 

  

	 	I.	Sponsor intends to apply for a manufacturing site transfer for the BLA (“Site Transfer Approval”) in 2016 and expects a preapproval inspection in 2018 with routine commercial supply starting in 2019. Parties
agree that Fujifilm shall maintain [***] following the Conformance Campaign and prior to initiation of routine commercial supply, as follows: 

  

	 	a)	During the calendar year 2017, and in case of delays in the application for market authorization (“Application Delay”) during any of the following years of such delay, Fujifilm shall execute one Drug Substance
Manufacturing Campaign consisting of [***] including [***] (collectively, an “Engineering Run”.) The purpose of the Engineering Run will be to maintain staff training and test manufacturing readiness of equipment and facilities. The
Engineering Run(s) will be performed using GMP documentation and will include in-process and Product testing in Quality Control laboratories, but will [***]. The product from the Engineering Run(s) will not be suitable for human use. The Engineering
Run(s) will [***]. Sponsor and Fujifilm may agree to implement Process changes and/or improvements during the Engineering Run(s). The Parties shall agree on a Change Order in accordance with Section 11 below prior to implementation of any such
changes or improvements and Sponsor shall carry the regulatory and financial risk resulting from such implementation. 

  

	 	b)	During the calendar year 2018, or in the case of Application Delay during the year when a preapproval inspection is scheduled, Fujifilm shall execute a cGMP manufacturing campaign consisting of at least [***] Batches
(“cGMP Manufacturing Campaign”), providing that Fujifilm shall make a commercially reasonable effort to execute the cGMP Manufacturing Campaign to coincide with the regulatory preapproval-inspection. If more Batches are required, Sponsor
and Fujifilm shall agree on the number and timing of such Batches in a Change Order. The Drug Substance resulting from the cGMP Manufacturing Campaigns will comply with [***] of this Agreement. 

 

	 	d)	Annual Planning Process 

  

	 	I.	Fujifilm, Sponsor and Sponsor’s Commercial Partners shall meet at least once a year, no later than [***] and then no later than [***] of each of the following years of the Term for an Annual Planning Meeting to:

  

	 	a.	align [***] for the following calendar year. 

  

	 	b.	agree on the [***] for the following calendar year. 

  

	 	c.	create a [***] that reflects the [***] at least one [***]. 

  

	 	d.	agree on [***] 

  

	 	e.	agree on the [***] 

  

	 	f.	agree on [***] in accordance with the [***]. 

  

	 	II.	After completion of the manufacturing campaign for any given year, Sponsor and the Commercial Partners will meet to review [***] of Drug Substance produced and [***] of Drug Substance [***], following the methodology in
Attachment 3. 

  

	 	e)	Product Rolling Forecast. 

  

	 	I.	Before the end of the first month of each quarter, Sponsor and the Sponsor’s Commercial Partners shall provide Fujifilm an updated [***] rolling manufacturing forecast (“Rolling Manufacturing Forecast”)
that includes both the [***], starting with the following quarter and a long term forecast (“Long Term Forecast”) for months [***]. Except for the [***] Forecast (hereinafter defined), the Rolling Manufacturing Forecasts will not be
binding on Sponsor. 

  

			
	CONFIDENTIAL	  	8
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	II.	Sponsor and the Sponsor’s Commercial Partners shall provide Fujifilm with the first Rolling Manufacturing Forecast no later than [***]. 

 

	 	III.	The Rolling Manufacturing Forecast shall be constructed in such a way that the increase or decrease in the number of required Batches from one calendar year to the next calendar year does not exceed [***], rounded up in
case of an increase or rounded down in case of a decrease. A forecast that does not meet such criteria shall not be binding to Fujifilm, unless accepted in writing. If Fujifilm does not accept the forecast, Parties shall meet to negotiate a forecast
that is acceptable to both Parties. 

  

	 	IV.	Subject to Section 4(e)(III), the Rolling Manufacturing Forecast provided in the fourth quarter of a calendar year (each a “[***] Forecast”) shall become an order for the next [***] with the order periods
as follows: 

  

	 	a.	Binding Period. Months [***] of each [***] Forecast shall become the Binding Order for the next [***]. 

  

	 	b.	[***]. Months [***] of each [***] Forecast shall be [***] as follows: Except for the First Binding Period (hereinafter defined), for which this Section 4.e) IV.b. does not apply, the forecast for the Binding Period
included in each subsequent [***] Forecast will be at least [***] (rounded up) of the amount forecasted for the [***] in the immediately preceding [***] Forecast (or the Minimum Annual Order, whichever is greater) but no more than [***] (rounded
down) of the amount forecasted for the [***] in the immediately preceding [***] Forecast (or the Maximum Annual Order, whichever is less). 

  

	 	c.	Long Term Forecast Period spanning the months [***] shall be used for long term planning only and shall not be binding on any Party 

  

	 	d.	A Purchase Order(s) reflecting the Binding Order for the next [***] shall be delivered to Fujifilm by Sponsor and Sponsor’s Commercial Partner no later than [***] of the year preceding the Binding Period.

  

	 	f)	First Binding Period.  

  

	 	I.	The first Binding Period shall be the calendar year 2019, or in case of delay in the Site Transfer Approval, the first calendar year following the Site Transfer Approval (“First Binding Period”).

  

	 	II.	Sponsor shall submit a Purchase Order for the First Binding Period according to Section 4(e) no later than [***] or [***] of the year of Site Transfer Approval. 

 

	 	III.	During the First Binding Period and each subsequent Binding Period Fujifilm shall: 

  

	 	a.	Manufacture the Drug Substance Batches specified in the applicable [***] and resulting Purchase Order. 

  

	 	b.	Establish an Intermediate Safety Stock according to Section 4(a). 

  

	 	g)	Change within Binding Period 

  

	 	•	 	If the Sponsor or the Sponsor’s Commercial Partners request increase of number of Batches within a Binding Period Fujifilm shall [***]. Within [***] business days after receiving information from Fujifilm that they
can add to the Binding Order, Sponsor and/or Sponsor’s Commercial Partner, as applicable, shall issue a Purchase Order for such number of Batches. The payments for the additional Batches shall follow the procedure in [***]. Such additional
Batches shall become part of the Binding Order for the Binding Period and shall be purchased by Sponsor at the same [***]. 

  

	 	h)	Scheduling.  

  

			
	CONFIDENTIAL	  	9
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	I.	Within [***] following the Annual Planning Meeting, Fujifilm shall confirm the preliminary manufacturing schedule, or propose an alternative schedule that takes into account [***], and shall provide Sponsor with [***].

  

	 	II.	Fujifilm shall promptly inform Sponsor of any material changes in the [***]. 

  

	 	i)	Orders Before First Binding Period. Fujifilm agrees to use commercially reasonable efforts to Manufacture Drug Substance which may be ordered by Sponsor after the Site Transfer Approval but before the First
Binding Period, if any. 

 Section 5 

Sponsor Deliverables 
  

	 	a)	Timely Provision. Sponsor shall provide Sponsor Deliverables to Fujifilm on a timely basis. Sponsor will be solely responsible (as between Sponsor and Sponsor’s Commercial Partners) to timely provide
Fujifilm with adequate supply of Starting Material. The Starting Material will meet the necessary quantity and quality requirements for Fujifilm to Manufacture the Intermediate and Drug Substance for Sponsor and Sponsor’s Commercial Partners.
Failure by Sponsor to provide Sponsor Deliverables, including appropriate amounts of Starting Material as required for Manufacturing under Binding Orders plus appropriate quantity of back-up Starting Material on a timely basis and otherwise as
necessary to execute the Program for Sponsor and Sponsor’s Commercial Partner’s without delay, may result in additional charges to Sponsor and a possible delay in meeting Program objectives. 

 

	 	b)	Title to Sponsor Deliverables. Title to Sponsor Deliverables shall remain with Sponsor. Fujifilm shall not sell, pledge, hypothecate, dispose of, or otherwise transfer any interest in Sponsor Deliverables except
as otherwise provided in this Agreement. Notwithstanding the foregoing, Sponsor acknowledges and agrees that Starting Material may be used in the manufacture of Intermediate and/or Drug Substance for Sponsor’s Commercial Partners. Fujifilm
shall provide safe and secure storage conditions for Sponsor Deliverables while they are at Fujifilm’s location. Upon termination or expiration of this Agreement for any reason, Fujifilm will return to Sponsor all unused Sponsor Deliverables
which have been delivered to Fujifilm by Sponsor within [***] of such termination. 

 Section 6 

Compliance with Government Regulations 
  

	 	a)	GMP Facility. Intermediate and Drug Substance shall be Manufactured in Fujifilm’s GMP Facility. Fujifilm shall operate the GMP facility in compliance with Applicable Law and any requirements provided for in
the Quality Agreements. Fujifilm shall not permit debarred persons to participate in any Program. Fujifilm shall undertake reasonable steps to prevent such participation. 

 

	 	b)	Regulatory Strategy. Sponsor shall have the right and responsibility for determining regulatory strategy, decision and actions relating to a Program and the applicable Drug Substance and, subject to each
party’s contractual obligations under this Agreement, Fujifilm shall have the right and responsibility for determining regulatory strategy, decision and actions to the extent relating to (i) the Facility; (ii) Fujifilm’s quality
systems; (iii) any requirement imposed on Fujifilm by a Regulatory Authority or (iv) any other commitments made by Fujifilm prior to the Effective Date of this Agreement. Fujifilm hereby represents that to [***], no requirement imposed on
[***] as of the Effective Date or any other [***] or prevent Fujifilm from performing the Program or otherwise complying with its obligations hereunder. 

  

			
	CONFIDENTIAL	  	10
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	c)	Regulatory Changes. If U.S. government regulatory requirements change or if the mutually agreed upon expansion of the definition of “Regulatory Authority” impacts Fujifilm’s regulatory obligations
hereunder, Fujifilm will use reasonable efforts to satisfy the new requirements. In the event that compliance with such new applicable regulatory requirements necessitates a change in the Program, Fujifilm will submit to Sponsor a Change Order for
such affected Program or Programs in accordance with Section 11 of this Agreement. 

  

	 	d)	Information and Knowledge. Sponsor will provide Fujifilm with all the information and knowledge necessary to carry out the Program correctly in accordance with regulations in force, and any marketing
authorization for the Product. Sponsor will ensure that Fujifilm is fully aware of any problems associated with the Product or the Program which might pose a hazard to Fujifilm’s premises, equipment, personnel, other materials or
other products. 

  

	 	e)	Regulatory Conflicts. In the event of a conflict in government regulations, Sponsor and Fujifilm will agree which regulations shall be followed by Fujifilm in its performance of the Program to comply with
regulatory requirements and advance such Program. 

 Section 7 

Facility Visits 
 The terms and conditions of
Sponsor audits and other visits are provided in the Quality Agreement. 
 Section 8 

Process Consumables and Safety Stock 
  

	 	a)	Process Consumables. Fujifilm shall procure sufficient Process Consumables to meet Manufacturing requirements specified in a Binding Order. Process Consumables Category A and Process Consumables Category B will
be allocated to individual Batches. Process Consumables Category C will be used no more than [***] times in a Downstream Campaign. If a Downstream Campaign is greater than [***] Drug Substance Batches, a new order of Process Consumables Category C
will be used after each [***] Drug Substance Batches. Process Consumables Category C shall not be reused for Downstream Campaigns which are not Manufactured in succession, unless otherwise agreed by Parties in writing. Sponsor recognizes that
Fujifilm may be required to purchase quantities of Process Consumables in excess of the amount actually consumed in the Manufacture of Intermediate and Drug Substance under Binding Order(s) due to minimum purchase quantity, overages of resins needed
for proper packing or columns, overage of materials needed for proper weigh-outs, or similar requirements. 

  

	 	b)	 Process Consumables Safety Stock. In addition to Process Consumables required for Manufacturing, Fujifilm
shall carry a safety stock of Process Consumables for uninterrupted Manufacturing of Drug Substance (“Safety Stock”). [***] for establishing a Safety Stock of Process Consumables Category A sufficient to fulfill obligations under
Binding Orders. No later than [***] from the date of [***] of the [***], Fujifilm and Sponsor shall jointly determine the required initial level of Safety Stock of Process Consumables Category B and Process Consumables Category C. Sponsor shall
carry the expense of 

  

			
	CONFIDENTIAL	  	11
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	
procurement of initial Process Consumables Category B and Process Consumables Category C, establishing their required initial Safety Stock, and any future adjustments to the Safety Stock.
Fujifilm shall rotate the Process Consumables in the Safety Stock and shall be [***] the Safety Stock of Process Consumables Category B and Process Consumables Category C. Pricing and invoicing for the initial Safety Stock of Process Consumables
Category B and Process Consumables Category C is set forth in Section 9(e). 

  

	 	c)	Delays in Obtaining Process Consumables. Fujifilm shall not be responsible or liable to Sponsor for any difficulties or delays in obtaining Process Consumables which cannot be obtained due to supplier shortages
or supplier quality issues; to the extent such difficulties or delays are not caused by Fujifilm negligence. 

  

	 	d)	Disposal of Expired or Unused Process Consumables and Safety Stock. Fujifilm shall be responsible for disposal of expired or unused Process Consumables. The cost of such Process Consumables and their disposal
shall be borne by Fujifilm except of Process Consumables from Safety Stock not regularly stocked by Fujifilm, disposal cost of which shall be borne by Sponsor unless such Process Consumables are expired or unused due to Fujifilm’s delay in the
commencement of a Campaign for reasons other than Sponsor delay. Fujifilm shall invoice Sponsor for disposal of any Process Consumables from the Safety Stock not regularly stocked by Fujifilm, except as set forth in the preceding sentence.

 Section 9 
 Compensation

  

	 	a)	Payments for Engineering Run(s). Sponsor shall pay for Engineering Run as follows: 

  

	 	i.	[***] of the Engineering Run Price by [***] of the year preceding the calendar year in which the Engineering Run is scheduled 

  

	 	ii.	[***] of the Engineering Run Price [***] 

  

	 	iii.	[***] of the Engineering Run Price [***] 

  

	 	iv.	[***] of the Engineering Run Price [***]. 

  

	 	b)	Payments for Batches to be manufactured in the cGMP Manufacturing Campaign before the Initial Binding Period, including but not limited to Batches to be produced concurrently with the pre-approval inspection:

  

	 	i.	[***] of cumulative price for all such Batches ordered upon submission of a purchase order, but no later than the Sponsor’s submission for market authorization leading to the pre-approval inspection

  

	 	ii.	[***] of cumulative price for all such Batches upon [***] 

  

	 	iii.	[***] of cumulative price for all such Batches upon [***] 

  

	 	iv.	[***] of Batch Price [***]. The corresponding payment for each such Batch will be invoiced separately upon shipment of such Batch. 

  

	 	c)	Payments for Batches Manufactured Under Binding Orders. Sponsor shall pay for Batches of Product specified in Binding Order as follows: 

 

	 	i.	[***] of Binding Order upon submission of Purchase Order 

  

	 	ii.	[***] of Binding Order [***] 

  

	 	iii.	[***] of Binding Order [***] 

  

	 	iv.	[***] of Binding Order [***]. The corresponding payment for each Batch will be invoiced separately upon shipment of such Batch. 

  

			
	CONFIDENTIAL	  	12
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	d)	Intermediate Safety Stock. 

  

	 	i.	Sponsor shall pay for establishment of and any increase of Intermediate Safety Stock as follows 

  

	 	a.	[***] of Intermediate Batch Price for Intermediate Batches specified in the Intermediate Safety Stock Purchase Order upon submission of the Purchase Order 

 

	 	b.	[***] of Intermediate Batch Price for Intermediate Batches specified in the Intermediate Safety Stock Purchase Order [***]. 

  

	 	ii.	If Sponsor requests a reduction of Intermediate Safety Stock, Fujifilm shall not replenish the excess of Intermediate Safety Stock and shall [***]. 

 

	 	e)	Process Consumables Safety Stock. Fujifilm shall invoice Sponsor for the cost of Process Consumables Category B and Process Consumables Category C Safety Stock plus a [***] fee for [***] upon [***].

  

	 	f)	Campaign Fee. The Campaign Fee will be invoiced on start of an [***]. 

  

	 	g)	Annual Program Fee. In addition to fees for Drug Substance delivered under Binding Orders, Sponsor shall pay Fujifilm the Annual Program Fee listed in Attachment 1. The Annual Program Fee for a calendar year
shall be invoiced at the beginning of that year. 

  

	 	h)	Annual Price Adjustment. 

  

	 	I.	The Manufacturing Price, Campaign Report Fee, Engineering Run Price and Annual Program Fee specified in Attachment 1 shall increase first on [***] and then on [***] of
the consecutive years in an amount [***], if any, [***]. Manufacturing Price shall not decrease. Notwithstanding the foregoing, if [***]. 

  

	 	II.	Process Consumable Price and Resin Price specified in Attachment 2 shall be adjusted annually first on [***] and then on [***] of the consecutive years in the amount equal to the increase
or [***]. 

  

	 	i)	Process Improvements. The Parties agree that during the course of the Agreement, the Parties may identify and implement process improvements that can benefit both Parties. If one of the Parties identifies an
opportunity for improvements related to raw materials, such Party will notify the other Party and the Parties will jointly discuss and use good faith efforts to agree to these opportunities. Any cost-related improvements resulting from these
projects will be shared across both Parties, with [***] of the cost savings being passed through to Sponsor. Such improvements must be within the validated parameters of the process and shall not be effective unless mutually agreed in writing by the
Parties and approved by relevant regulatory authorities. 

  

	 	j)	[***]. 

  

	 	k)	Payment Terms. Payments are due thirty (30) calendar days from the date of invoice issued by Fujifilm. Payments received beyond thirty (30) calendar days from the date of invoice are subject to an
interest charge of one percent (1%) per month. Unless within thirty (30) calendar days of the date of invoice, Sponsor has advised Fujifilm in good faith and in writing the specific basis for disputing an invoice, failure to pay an invoice
within seventy-five (75) days from the date of invoice may, at Fujifilm’s election, constitute a material breach of this Agreement. 

  

			
	CONFIDENTIAL	  	13
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	l)	Suspension of Services. In addition to all other remedies available to Fujifilm, in the event of a Sponsor default, including if Sponsor fails to make payments as required hereunder, provided such payments are
not disputed, Fujifilm may refuse to carry out further work and/or suspend Manufacture and deliveries of Drug Substance or provision of other services and reports until Sponsor makes payment and/or provides assurance of further or future payment
reasonably satisfactory to Fujifilm. 

  

	 	m)	Sponsor-dedicated Process Equipment. In anticipation of commercial supply of the Drug Substance, Fujifilm shall perform evaluation of the equipment used in Manufacturing of Drug Substance in respect to the risk
posed to uninterrupted supply of Drug Substance under this Agreement and shall propose to Sponsor appropriate countermeasures that may include dedication of equipment to the Program. If Sponsor elects to have any equipment dedicated solely to the
Program, Sponsor shall carry the cost of procurement, installation and qualification of such equipment, which shall be set forth in a Change Order 

Section 10 
 Non-Conforming Batch 

 

	 	a)	Non-Conforming Batch. The following provisions shall apply if it is ascertained by either Party that a Drug Substance Batch is a Non-Conforming Batch: 

 

	 	I.	If Fujifilm is the first to discover the non-conformity, Fujifilm shall provide written notice of same, including an explanation of the non-conformity, to Sponsor within the period specified in the Quality Agreement, If
Sponsor is the first to discover the non-conformity, Sponsor shall provide written notice, including an explanation of the non-conformity, within the period specified in the Quality Agreement. If Sponsor does not provide notice of non-conformity in
the time frame set forth above, Sponsor shall be deemed to have accepted such Drug Substance Batch. 

  

	 	II.	The Non-Conforming Batch shall not be delivered to Sponsor if it is still located at the GMP Facility on the date of Fujifilm’s issuance or receipt (as applicable) of the notice of non-conformity.

  

	 	III.	If Sponsor has provided the notice of a Non-Conforming Batch to Fujifilm within the period specified in Quality Agreement, Fujifilm shall investigate the non-conformity in accordance with the Quality Agreement and
notify Sponsor in writing as to whether Fujifilm agrees or disagrees in good faith with Sponsor’s determination of the existence or cause of the non-conformity and the reasons therefor. 

 

	 	IV.	If Fujifilm has provided the notice of a Non-Conforming Batch to Sponsor within the period specified in the Quality Agreement, Sponsor shall notify Fujifilm whether Sponsor agrees or disagrees in good faith with
Fujifilm’s determination of the existence or cause of the non-conformity and the reasons therefore. If Sponsor does not provide a written notice within such period, Sponsor shall be deemed to have accepted the existence and cause of
non-conformity as stated by Fujifilm. 

  

			
	CONFIDENTIAL	  	14
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	V.	In the event the Parties do not agree as to the existence of a Non-Conforming Batch or the cause of the Non-Conforming Batch for purposes of 10(c), then within [***] days of Fujifilm’s written notice pursuant to
Section 10(a)(iv) or Sponsor’s written notice pursuant to Section 10(a)(iii), the parties shall follow dispute resolution as set forth in Section 18 where “senior executive” shall mean the head of a Quality Assurance
unit. 

  

	 	VI.	Fujifilm shall use commercially reasonable efforts to start Manufacture of a further Batch to replace the Non-Conforming Batch at [***]. In addition, [***], if applicable pursuant to [***]. Notwithstanding the
foregoing, [***]. 

  

	 	b)	Disposal of Non-Conforming Batch. Unless otherwise requested by Sponsor in writing, Fujifilm shall dispose of any Non-Conforming Batch that [***] pursuant to [***] in accordance with Applicable Law and at
Fujifilm’s cost. 

  

	 	c)	Change in Process Performance and Multiple Non-Conforming Batches. In the event the Parties mutually agree a root cause of non-conformity of a Non-Conforming Batch is attributed to change in process performance
or when for two or more Non-Conforming Batches within a Campaign, the root cause is not identifiable and is not the result of Fujifilm’s failure to perform the Manufacturing in accordance with this Agreement and the Quality Agreement, [***]. In
addition, to the extent required for compliance with cGMP, Fujifilm may postpone the start date of any further Batches pending [***]. 

  

	 	d)	Limited Remedy. Notwithstanding anything to the contrary in this Agreement, the remedies set out in this Section 10 shall be Sponsor’s sole remedies in relation to a Non-Conforming Batch.

  

	 	e)	Reliance on Terms of Agreement in Accepting/Rejecting Batch. For the avoidance of doubt, the Parties will follow the terms in this Agreement and the Quality Agreement for accepting or rejecting a disputed Batch.

 Section 11 
 Change Orders

  

	 	a)	Assumptions. The Batch Price, Annual Program Fee and Campaign Fee are subject to the following assumptions that (a) a validated Process and analytical methods will be used to Manufacture Intermediate and
Drug Substance, with no changes following the Conformance Campaign; (b) there will be no changes to the Drug Substance Specification or the Specification following the Conformance Campaign; (c) there will be no changes to the Specification
documented in Sponsor’s BLA, (d) no additional process development, process qualification or validation, and no analytical development, qualification or validation will be required under this Agreement, and (e) Drug Substance
stability programs (if required) will be managed through separate contracts and their outcome will not require changes to the process (“Key Manufacturing Assumptions”). Fujifilm also assumes that Sponsor will cooperate and perform
its obligations under this Agreement in a timely manner, that no event described in Section 21, (Force Majeure) will occur and that there are no changes to any applicable laws, rules or regulations which affect the timely performance of the
Program (the foregoing assumptions together with the Key Manufacturing Assumptions, collectively, the “Assumptions”). 

  

			
	CONFIDENTIAL	  	15
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	b)	Sponsor Change Orders. Sponsor shall inform Fujifilm in writing of any proposed modifications to the Key Manufacturing Assumption, equipment, systems, GMP Facility, Process, Process Consumables, Starting
Materials, Specifications or other changes relating to the Manufacture (collectively, “Modifications”). Once a Modification has been requested by Sponsor, and agreed with by Fujifilm, Fujifilm shall provide Sponsor with a change
order containing an estimate of the increase or decrease, as applicable, in Batch Price or any other costs to Sponsor as well as the activities, deliverables, estimated duration, and payment schedule (“Change Order”) within [***]
business days of receiving such request from Sponsor. Sponsor shall be deemed to have not approved the Change Order if Fujifilm does not receive a written approval of the Change Order from Sponsor within [***] business days of Sponsor’s receipt
of the Change Order. If Sponsor does not approve such Change Order, then Sponsor and Fujifilm shall negotiate in good faith to agree on a Change Order that is mutually acceptable. Any Modification proposed by Sponsor that would materially and
negatively impact Fujifilm’s ability to perform services (including, without limitation, meeting its then-existing contractual obligations) for then-existing third party clients or that require more than commercially reasonable efforts by
Fujifilm to implement shall be discussed by the parties in good faith and shall require Fujifilm’s prior written consent, which consent shall not be unreasonably withheld or delayed. 

 

	 	c)	Fujifilm Change Orders. Fujifilm shall promptly notify Sponsor in writing of any Modification after becoming aware of the need for such Modification. If a Modification is expected to have an impact on Process,
Product, the BLA, or Fujifilm obligations under this Agreement, the Parties shall discuss the feasibility of such Modification in good faith. Any changes to Agreement, including pricing, resulting from such Modification shall be subject to the
Change Order process. Fujifilm shall request Modifications in writing from Sponsor by issuing a Change Order to Sponsor for review and approval. Sponsor shall be deemed to have not approved the Change Order if Fujifilm does not receive a written
approval of the Change Order from Sponsor within [***] business days of Sponsor’s receipt of the Change Order. If Sponsor does not approve such Change Order, then Sponsor and Fujifilm shall negotiate in good faith to agree on a Change Order
that is mutually acceptable. 

  

	 	d)	Modifications Requested by Regulatory Authority. If Modifications are requested by or from Fujifilm or Sponsor as a result of requirements set forth by a Regulatory Authority and such Modifications apply solely
to the Manufacture of Drug Substance, then Sponsor and Fujifilm will review such requirements and use good faith efforts to agree on the reasonable costs associated therewith, which shall be borne by Sponsor. If Modifications are requested by or
from Fujifilm as a result of requirements set forth by a Regulatory Authority and such Modifications apply generally to the Drug Substance as well as other products produced by Fujifilm (for itself or for third parties) or the general operation of
the Facilities, then Fujifilm shall bear the reasonable costs associated therewith. Except as set forth above, the reasonable costs associated with Modifications requested by Fujifilm which exclusively benefit Fujifilm and/or its other customers
shall be borne by Fujifilm, and the reasonable costs associated with Modifications requested by Sponsor shall be borne by Sponsor. 

  

	 	e)	 Regulatory Authority Approval of Modifications. Sponsor shall have sole responsibility for obtaining any
and all necessary approvals from any Regulatory Authority for implemented Modifications and for reporting any implemented Modifications to any Regulatory Authority as appropriate, except if Modifications are requested by or from Fujifilm as a result
of requirements set forth by a Regulatory Authority and such 

  

			
	CONFIDENTIAL	  	16
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	
Modifications apply generally to the Drug Substance as well as other products produced by Fujifilm (for itself or for third parties) or the general operation of the Facilities, in which case
Fujifilm shall have the responsibility for the aforementioned actions. Upon request by a Party, the other Party shall assist in obtaining any such approvals; provided that Sponsor will pay Fujifilm reasonable fees therefor to the extent Sponsor
is responsible for the costs of the Modification, such fees being reflected in their respective Change Order. 

 Section 12 

Confidential Information/Legal Proceedings 
  

	 	a)	Sponsor’s Confidential Information. For the duration of this Agreement and for [***] years thereafter, Fujifilm will not disclose, without Sponsor’s written permission, any Confidential Information
disclosed (whether disclosed in writing, verbally, by way of sample or by any other means and whether directly or indirectly) by Sponsor (“Sponsor’s Confidential Information”) unless such disclosure: (i) is to an Affiliate
of Fujifilm that is under a similar obligation to keep such information confidential; (ii) is or becomes publicly available through no fault of Fujifilm; (iii) is disclosed to Fujifilm by a third party entitled to disclose it; (iv) is
already known to Fujifilm as shown by its prior written records; (v) is developed independently of a Program by Fujifilm without reference to any of the Confidential Information disclosed by Sponsor; or (vi) is required by any law, rule,
regulation, order decision, decree, subpoena or other legal process to be disclosed. If such disclosure is requested by legal process, Fujifilm will make all reasonable efforts to notify Sponsor of this request promptly prior to any disclosure to
permit Sponsor to oppose such disclosure by appropriate legal action. Fujifilm shall use reasonable precautions to protect the confidentiality of Sponsor’s Confidential Information comparable to precautions taken to protect its own proprietary
information. Fujifilm will not use Sponsor’s Confidential Information for any purpose except performing its obligations under this Agreement. Upon termination or expiration of this Agreement for any reason, Fujifilm will return to Sponsor all
Sponsor’s Confidential Information within thirty (30) days of such termination, except that Fujifilm may retain one copy of Sponsor’s Confidential Information to the extent Fujifilm is required to do so under the Quality Agreement or
for regulatory purposes. 

  

	 	b)	 Fujifilm Confidential Information. For the duration of this Agreement and for [***] years thereafter,
Sponsor will not disclose, without Fujifilm’s written permission, any Confidential Information disclosed (whether disclosed in writing, verbally, by way of sample or by any other means and whether directly or indirectly) by Fujifilm to Sponsor
in connection with Fujifilm’s performance of any Program (“Fujifilm Confidential Information”) unless such disclosure: (i) is to an Affiliate of Sponsor that is under a similar obligation to keep such information
confidential; (ii) is or becomes publicly available through no fault of Sponsor; (iii) is disclosed to Sponsor by a third party entitled to disclose it; (iv) is already known to Sponsor as shown by its prior written records;
(v) is developed independently of a Program by Sponsor without reference to any of the Confidential Information disclosed by Fujifilm; or (vi) is required by any law, rule, regulation, order decision, decree, subpoena or other legal
process to be disclosed. If such disclosure is requested by legal process, Sponsor will make all reasonable efforts to notify Fujifilm of this request promptly prior to any disclosure to permit Fujifilm to oppose such disclosure by appropriate legal
action. Sponsor shall use reasonable precautions to protect the confidentiality of Fujifilm Confidential Information comparable to precautions taken to protect its own proprietary information. Sponsor will not use Fujifilm Confidential Information
for any purpose except performing its obligations under this Agreement. Upon termination or expiration of this Agreement for any reason, 

  

			
	CONFIDENTIAL	  	17
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	
Sponsor will return to Fujifilm all Fujifilm Confidential Information within thirty (30) days of such termination, except that Sponsor may retain one copy of Fujifilm’s Confidential
Information to the extent Sponsor is required to do so under the Quality Agreement or for regulatory purposes. 

  

	 	c)	Testimony and Records. If either Party shall be obliged to provide testimony or records constituting Confidential Information of the other in any legal or administrative proceeding, then the Party to whom the
Confidential Information belongs shall reimburse the other Party for its out-of-pocket costs therefore plus an hourly fee for its employees or representatives equal to the internal fully burdened costs of such employee or representative.

  

	 	d)	Definition. For both Parties, “Confidential Information” shall mean and include without limitation such types of information as: inventions, methods, plans, processes, specifications,
characteristics, raw data, analyses, equipment design, costs, marketing, sales, and performance information, including patents and patent applications, grant applications, notes, and memoranda, whether in writing or presented, stored or maintained
electronically, magnetically or by other means, which are disclosed by the disclosing Party to the recipient Party in writing or in other tangible form and marked “confidential” or, if disclosed orally (or in some other non-tangible form),
are identified as confidential to the recipient Party in writing within sixty (60) days of such disclosure. 

 Section 13 

Inventions and Patents 
  

	 	a)	Drug Substance improvement or use inventions discovered by Fujifilm employees during and as a result of performing a Program under this Agreement (“Drug Substance Invention”) shall be owned by Sponsor,
and Fujifilm hereby assigns all such Drug Substance Inventions to Sponsor. If Sponsor requests and at Sponsor’s expense, Fujifilm will execute any and all applications, assignments or other instruments and give testimony which shall be
necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to the Drug Substance Invention and Sponsor shall compensate Fujifilm for the time devoted to such activities and reimburse it for expenses
incurred. For Drug Substance Inventions assigned pursuant to this section, Sponsor shall provide Fujifilm a royalty-free license necessary to perform each Program for the term of this Agreement. All other inventions or improvements discovered solely
or jointly by Fujifilm employees during and as a result of performing the Program (“Process Inventions”) shall be owned by Fujifilm; provided that if a Process Invention directly related to rhPDGF-BB is jointly discovered by Sponsor
and Fujifilm, Fujifilm may not use such Process Invention in connection with third party customers for such customers’ rhPDGF-BB development or manufacture. 

  

	 	b)	For Process Inventions, Fujifilm will grant to Sponsor a perpetual, world-wide, royalty-free, non-exclusive license, with right to sublicense, under terms mutually agreed to by the Parties in and to such Process
Inventions for Sponsor to manufacture, and/or have a third party manufacture, the Drug Substance. If Fujifilm requests and at Fujifilm’s expense, Sponsor will execute any and all applications, assignments or other instruments and give testimony
which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to the Process Invention and Fujifilm shall compensate Sponsor for the time devoted to such activities and reimburse it for expenses
incurred. 

  

			
	CONFIDENTIAL	  	18
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	c)	Fujifilm reserves the right to use data during the course of a Program to support applications necessary to apply for and obtain Letters of Patent of the U.S. or any foreign country with respect to Process Inventions so
long as no Sponsor Confidential Information is disclosed in any such application. 

 Section 14 

Independent Contractor 
 Fujifilm shall perform each
Program as an independent contractor of Sponsor and shall have complete and exclusive control over its facilities, equipment, employees and agents. The provisions of this Agreement shall not be construed to establish any form of partnership, agency
or other joint venture of any kind between Fujifilm and Sponsor, nor to constitute either Party as the agent, employee or legal representative of the other. All persons furnished by either Party to accomplish the intent of this Agreement shall be
considered solely as the furnishing Party’s employees or agents and the furnishing Party shall be solely responsible for compliance with all laws, rules and regulations involving, but not limited to, employment of labor, hours of labor, working
conditions, workers’ compensation, payment of wages, and withholding and payment of applicable taxes, including, but not limited to income taxes, unemployment taxes, and social security taxes. 

Section 15 
 Insurance 

 

	 	a)	Fujifilm Insurance Obligations. Fujifilm shall secure and maintain in full force and effect throughout the performance of each Program policies of insurance for (a) workmen’s compensation
(b) general liability, (c) automobile liability, and (d) product liability having policy limits, deductibles and other terms appropriate to the conduct of Fujifilm’s business in Fujifilm’s reasonable judgment.

  

	 	b)	Sponsor Insurance Obligations. Sponsor shall secure and maintain in full force and effect throughout the performance of each Program policies of insurance for (a) general liability and (b) product
liability having policy limits, deductibles and other terms appropriate to the conduct of Sponsor’s business in Sponsor’s reasonable judgment. 

Section 16 
 Delivery 

Fujifilm shall package for shipment Drug Substance, samples or other materials at Sponsor’s expense and in accordance with Sponsor’s full written and
reasonable instructions with Sponsor bearing all packaging, shipping and insurance charges. Freight terms shall be Ex Works (Incoterms 2010). Fujifilm shall retain representative samples of Drug Substance for record keeping, testing and regulatory
purposes. Sponsor shall provide for shipping within fourteen (14) calendar days of receiving of a complete Batch Packet by Sponsor. In the event of any delay by Sponsor in shipping one or more shipments of Drug Substance in accordance with this
Section 16, the Parties acknowledge and agree that liability and risk of loss for each such shipment of Drug Substance shall automatically transfer to (and be assumed by) Sponsor effective upon expiration of the applicable fourteen
(14) day period. 
 Section 17 

Default/Limitation of Warranty 
  

	 	a)	 Fujifilm Default. If Fujifilm is in default of its material obligations under this Agreement, then Sponsor
shall promptly notify Fujifilm in writing of any such default. Fujifilm shall have a period of forty-five (45) days from the date of receipt of such notice within which to cure or to commence to cure such default. If Fujifilm fails to so cure
or commence to cure, then this Agreement shall, at Sponsor’s option, immediately terminate. Subject to 

  

			
	CONFIDENTIAL	  	19
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	
any limitations of remedies and liability limitations, including without limitation, those set forth in Section 10 (d) and Sections 17(c) and (d), in the event of such termination,
Sponsor will also be entitled to all other rights and remedies available at law or in equity. 

  

	 	b)	Sponsor Default. If Sponsor is in default of its material obligations under this Agreement, Fujifilm shall promptly notify Sponsor in writing of any such default. Sponsor shall have a period of forty-five
(45) days from the date of receipt of such notice within which to cure such default; provided that if Sponsor fails to cure such breach within the specified cure period, this Agreement may, at Fujifilm’s option, immediately
terminate. Subject to any limitations of remedies and liability limitations, including without limitation, those set forth in Section 17(c), in the event of such termination, Fujifilm will also be entitled to all other rights and remedies
available at law or in equity. 

  

	 	c)	LIMITATION OF LIABILTY. Notwithstanding anything herein to the contrary, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE ENTITLED TO INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES ARISING IN CONNECTION WITH THE
DEFAULT OR BREACH OF ANY OBLIGATION OF THE OTHER PARTY UNDER THIS AGREEMENT OR ANY DOCUMENTS OR APPENDICES RELATED THERETO. [***]. The foregoing limitations on liability shall not apply to liability arising from [***] contained in
Section 12. 

  

	 	d)	DISCLAIMER OF WARRANTY. EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY PROVIDES TO THE OTHER PARTY HERETO ANY WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE MATERIALS AND SERVICES PROVIDED
HEREUNDER, AND ALL SUCH WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE WAIVED. 

 

	 	e)	[***].

 Section 18 

Dispute Resolution 
  

	 	a)	Executive Discussions. In the event any dispute shall arise between Sponsor and Fujifilm with respect to any of the terms and conditions of this Agreement or a Program; then senior executives of Sponsor and
Fujifilm shall meet as promptly as practicable after notice of such dispute to resolve in good faith such dispute. 

  

	 	b)	Mediation. If Sponsor and Fujifilm are unable to satisfactorily resolve the dispute within [***] following referral to the senior executives through provision of a written notice by one of the Parties as set
forth in Section 28, then such dispute shall be referred to mediation in accordance with the rules of the American Arbitration Association. The Parties shall participate in the mediation in a good faith attempt to settle the dispute. The
mediation shall be held in Wake County, North Carolina. 

  

	 	c)	 Arbitration. If mediation fails to resolve the dispute within [***] of the initial meeting pursuant to
Section 18(a) above, then such dispute shall be finally settled by an arbitrator in accordance with this Section 18(c). The arbitration will be held in Wake County, North Carolina, and except as noted below, shall be conducted in
accordance with the rules of the American Arbitration Association by a neutral arbitrator agreeable to both Parties. If the Parties do not agree on an arbitrator within [***] of the termination of the mediation as indicated by at least one of the
Parties, the American Arbitration Association shall appoint an arbitrator to hear the case in accordance with its rules. The 

  

			
	CONFIDENTIAL	  	20
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	
arbitrator shall have no authority to award consequential or exemplary damages or to vary from or ignore the terms of this Agreement and shall be bound by controlling law. Finally, the Parties
may seek judicial intervention for emergency relief, such as restraining orders and injunctions where appropriate, and for specific performance as provided in Section 17(e) above. 

 

	 	d)	Binding Decision. Any decision by the arbitrator shall be binding upon the Parties and may be entered as final judgment in any court having jurisdiction. The cost of any arbitration proceeding shall be borne by
the Parties, as the arbitrator shall determine if the Parties have not otherwise agreed. The arbitrator shall render their final decision in writing to the Parties. 

 

	 	e)	Timeliness of Actions. Any action for breach of this Agreement or to enforce any right hereunder shall be commenced pursuant to this Section 18 within [***] after the cause of action accrues or it shall be
deemed waived and barred, except any action for nonpayment by Sponsor of any prices, charges, fees or other amounts payable hereunder may be brought by Fujifilm at any time permitted by applicable law, and Fujifilm may suspend performance of any of
its obligations hereunder until all such payments are made. 

 Section 19 

Indemnification 
  

	 	a)	Fujifilm Indemnification Obligations. Fujifilm shall indemnify Sponsor and its affiliates and their respective officers, directors and employees (collectively, the “Sponsor Group”) from any loss, cost,
damage or expense (“Loss”) from any lawsuit, action, claim, demand, assessment or proceeding (“Claim”) arising from (i) Fujifilm’s negligence, gross negligence or intentional misconduct or inaction in the
performance of this Agreement, or (ii) Fujifilm’s violation, non-compliance or non-performance of any of the terms of this Agreement; provided that if such Loss or Claim arises in whole or in part from Sponsor’s negligence,
gross negligence or intentional misconduct or inaction, then the amount of the Loss that Fujifilm shall indemnify the Sponsor Group for pursuant to this Section 19(a) shall be reduced by an amount in proportion to the percentage of
Sponsor’s responsibilities for such Loss determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement between the Parties. 

 

	 	b)	Sponsor Indemnification Obligations. Sponsor shall indemnify Fujifilm and its affiliates and their respective officers, directors and employees (collectively, the “Fujifilm Group”) from any Claim
or Loss arising from or related to: (i) the Sponsor Deliverables, Drug Product or the Program; (ii) the negligence, gross negligence or intentional misconduct or inaction of Sponsor; (iii) the infringement or alleged infringement of
the Drug Substance or Starting Materials or other information or materials supplied to Fujifilm by or on behalf of Sponsor on the intellectual property rights of a third party; or, (iv) Sponsor’s violation, non-compliance or
non-performance of any of the terms of this Agreement; provided that if such Loss or Claim arises in whole or in part from Fujifilm’s negligence, gross negligence or intentional misconduct or inaction, then the amount of such Loss that
Sponsor shall indemnify the Fujifilm Group for pursuant to this Section 19(b) shall be reduced by an amount in proportion to the percentage of Fujifilm’s responsibilities for such Loss as determined by a court of competent jurisdiction in
a final and non-appealable decision or in a binding settlement between the Parties. 

  

	 	c)	 Indemnification Procedure. Upon receipt of notice of any Claim which may give rise to a right of indemnity
from the other Party hereto, the Party seeking indemnification (the 

  

			
	CONFIDENTIAL	  	21
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	
“Indemnified Party”) shall give written notice thereof to the other Party, (the “Indemnifying Party”) with a Claim for indemnity (“Indemnity
Claim”). Any delay or failure to give notice shall not discharge the duty of the Indemnifying Party to indemnify except to the extent it is prejudiced by such delay or failure. Such Claim for indemnity shall indicate the nature of the Claim
and the basis therefore. Promptly after a Claim is made for which the Indemnified Party seeks indemnity, the Indemnified Party shall permit the Indemnifying Party, at the Indemnifying Party’s option and expense, to assume the complete defense
of such Claim, provided that (i) the Indemnified Party will have the right to participate in the defense of any such Claim at its own cost and expense, (ii) the Indemnifying Party will conduct the defense of any such Claim with due
regard for the business interests and potential related liabilities of the Indemnified Party and (iii) the Indemnifying Party will, prior to making any settlement, consult with the Indemnified Party as to the terms of such settlement and
receive approval thereof, not to be unreasonably withheld. The Indemnifying Party will not, in defense of any such Claim, except with the consent of the Indemnified Party, consent to the entry of any judgment or enter into any settlement which does
not include as an unconditional term thereof, the giving by the claimant or plaintiff to the Indemnified Party of a release from all liability in respect thereof. As to those Claims with respect to which the Indemnifying Party does not elect to
assume control of the defense, the Indemnified Party will afford the Indemnifying Party an opportunity to participate in such defense at the Indemnifying Party’s own cost and expense, and will not settle or otherwise dispose of any of the same
without the consent of the Indemnifying Party. 

 Section 20 

Representations and Warranties 
  

	 	a)	Right and Authority. Each Party represents and warrants to the other that it has the full right and authority to enter into this Agreement and to perform in accordance with the terms and conditions set forth
herein. Each Party represents and warrants to the other that neither it nor any of its officers, directors, or its employees performing services under this Agreement has been debarred, or convicted of a crime which could lead to debarment, under the
Generic Drug Enforcement Act of 1992, 21 United States Code §§335(a) and (b). 

  

	 	b)	Licenses and Permits. Each Party represents and warrants to the other Party that it has obtained and will at all times during the term of this Agreement, hold and comply with all licenses, permits and
authorizations necessary to perform this Agreement as now or hereafter required under any applicable statutes, laws, ordinances, rules and regulations of the United States and any applicable foreign, state, and local governments and governmental
entities. 

  

	 	c)	Legal Title. Sponsor hereby represents and warrants to Fujifilm that it has legal title and/or a valid license to the cell line, raw material, expression systems, process patents and the Drug Substance necessary
to conduct the Program and that the Drug Substance will not violate or infringe on the patents, trademarks, trade names, service marks or copyrights of any other party. 

Section 21 
 Force Majeure 

Either Party shall be excused from performing its respective obligations under this Agreement if and to the extent that its performance is delayed or prevented
by Force Majeure. The Party subject to such event shall promptly notify the other Party of the occurrence thereof and, if known, the expected duration. Any time specified or estimated for completion of performance in

  

			
	CONFIDENTIAL	  	22
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 
the Agreement falling due during or subsequent to the occurrence of any of such events shall be automatically extended for a period of time to recover from such disability. Fujifilm will promptly
notify Sponsor if, by reason of any of the events referred to herein, Fujifilm is unable to meet any such time for performance specified or estimated in the Agreement. If any part of the Program is invalid as a result of such disability, Fujifilm
will, upon written request from Sponsor, but at Sponsor’s sole cost and expense, repeat that part of the Program affected by the disability. 

Section 22 
 Allocation of Resources 

If delays in the agreed commencement or performance of the Program occur because of Sponsor’s request or inability to supply Fujifilm with agreed Sponsor
Deliverables or any information required to begin or perform the Program within thirty (30) days of such agreed time, Fujifilm may reallocate resources being held for performance of the Program without incurring liability to Sponsor. In
addition, in such event Fujifilm shall be relieved of its obligation to perform the Program except that upon such delay being removed or remedied, Fujifilm will use commercially reasonable efforts to allocate resources to performance of the Program.

 Section 23 
 Use of Names 

The Parties anticipate opportunities for joint or independent press releases or other announcements relating to the activities contemplated hereby.
Notwithstanding the foregoing, except for SEC filings or other filings or releases required by law, neither Party shall use the name of the other Party, its Affiliates or the names of the employees of the other Party in any advertising or sales
promotional material or in any publication without prior written permission of such Party. Such consent may not be unreasonably withheld. In the event one Party is required to file an SEC filing or other filings or releases required by law,
such releasing Party shall provide the other Party with a copy of the release or a copy of this Agreement with proposed redactions as soon as reasonably practicable and with adequate time for review and response. Without limiting the foregoing, in
the event that either party must file a copy of this Agreement with the SEC or other governmental agency, such party shall provide the other party with a copy of this Agreement with proposed redactions with at least a twenty-one (21) day
opportunity to review and provide comments and additional redactions, unless the applicable SEC or agency requirements require a filing(s) which does not permit such twenty-one (21) day opportunity, in which case such party shall provide the
other party with a copy of this Agreement with proposed redactions with the maximum reasonable amount of time as possible to review and provide comments and additional redactions. The releasing Party shall incorporate the other Party’s
redactions in good faith. If the SEC or governmental agency does not accept such redactions, the releasing Party shall provide notice to the other Party and an opportunity to respond to the SEC (via the disclosing Party) and provide the copy of the
release or this Agreement as published. 
 Section 24 

Term/Termination 
  

	 	a)	Term. This Agreement shall commence as of the Effective Date and shall remain in force for an initial period of five (5) years from the Effective Date (“Initial Term”), unless sooner
terminated pursuant to Sections 17(a), 17(b) or 24(b). This Agreement shall automatically renew thereafter for successive three (3)-year periods (each an “Extension Term”) unless either party gives the other party at least
twenty-four (24) months’ notice of its intent to not renew this Agreement. The Initial Term and Extension Terms shall collectively be referred to herein as “Term”. 

  

			
	CONFIDENTIAL	  	23
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	b)	Termination for Bankruptcy. Either Party may immediately terminate this Agreement upon written notice to the other Party if (i) the other Party is declared insolvent or bankrupt by a court of competent
jurisdiction, (ii) a voluntary petition in bankruptcy is filed in any court of competent jurisdiction by the other Party or (iii) this Agreement is assigned by the other Party for the benefit of creditors. 

 

	 	c)	Survival of Terms. Definitions and the following sections shall survive termination or expiration of this Agreement: 9(i) (to the extent invoices are outstanding upon expiration or termination of this Agreement),
12, 13, 17(c), 17(d), 18, 19, 23, 24(c), 25, 27 – 32. 

 Section 25 

Sponsor Rights and Obligations upon Termination 
  

	 	a)	Supply of Drug Substance. Upon expiration or termination of this Agreement for any reason, Fujifilm shall manufacture, for supply to Sponsor: 

A. If the Agreement is terminated during the Initial Term or is not extended after the Initial Term: 

(i) [***] Batches of Drug Substance; or 

(ii) Any lesser number of Batches of Drug Substance agreed by Parties in writing at the expiration or termination of Agreement. 

B. If the Agreement is terminated during Extension Term or is not extended after any of the Extension Terms: 

(i) [***] of the number of Batches of Drug Substance ordered during the [***] period immediately preceding the effective date of such
expiration or termination; or 
 (ii) Any lesser number of Batches of Drug Substance requested by Sponsor in writing at the expiration or
termination of Agreement, but no less than [***] the Minimum Annual Order. 
 Sponsor shall be obligated to purchase from Fujifilm, and
Fujifilm shall be obligated to supply to Sponsor, all conforming Drug Substance so ordered under this Section 25(a), pursuant to the terms hereof (including, without limitation, Sections 9 and 16), within (i) [***], in case of Batches
manufactured under Section 25(a)(A), or (ii) [***], in case of Batches manufactured under Section 25(a)(B), of the effective date of the expiration or termination of this Agreement, unless otherwise agreed by Parties in writing
expressly stating that this purchase obligation will not apply. 
 Notwithstanding the foregoing, Fujifilm’s and Sponsor’s
obligations under this Section 25(a) will not apply if this Agreement is terminated by Fujifilm under under Section 17(b) or Section 24(b) hereof. Additionally, Fujifilm’s and Sponsor’s obligations under this
Section 25(a) will not apply if this Agreement is permitted to expire by mutual written agreement of the Parties expressly stating that this Section 25(a) will not apply. 

  

			
	CONFIDENTIAL	  	24
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	b)	Technical Transfer. Upon expiration or termination of this Agreement for any reason, upon Sponsor’s written request, at Sponsor’s reasonable cost and expense and subject to a Change Order, Fujifilm
shall: 

  

	 	i.	initiate a technical transfer of the Manufacturing Process to a third-party Contract Manufacturing Organization specified by Sponsor; provided, however, that in no event shall Fujifilm be required to (x) assign or
license any Fujifilm Intellectual Property Rights to such third party outside of the scope set forth in Section 13(b) of this Agreement or Section 10(b) of the MBSA in respect of Scope of Work #1 or any future Change Orders or Scopes of
Work (as defined in the MBSA) relating to the Product, or (y) assign, license or disclose to such third party any know-how or business information that, in Fujifilm’s reasonable assessment, may diminish its competitive position against
such third party. 

  

	 	ii.	provide Sponsor with Manufacturing Process Materials specified in Attachment 1, to the extent such materials have been generated under the Agreement, constitute Sponsor-specific work output, and have not been provided
to Sponsor in any form prior to such expiry or termination. 

 Notwithstanding the foregoing, Fujifilm’s obligations under
this Section 25(b) will not apply if this Agreement is terminated by Fujifilm under under Section 17(b) or Section 24(b) hereof or if the parties mutually agree in writing not to renew this Agreement, which writing expressly states
that this Section 25(b) will not apply. 
  

	 	c)	Regulatory Support. Upon expiration or termination of this Agreement for any reason, upon Sponsor’s written request, at Sponsor’s reasonable cost and expense, Fujifilm shall continue to provide
regulatory support to Sponsor directly related to Drug Substance, as provided in Section 3 c) and as otherwise required for Sponsor and Sponsor’s Commercial Partners to be able to market and sell the Drug Substance purchased under this
Section 25, and previously purchased under this Agreement, in the markets governed by the Regulatory Authorities. 

 Section 26 

Program Management 
  

	 	a)	Joint Steering Committee. Upon execution of this Agreement, Sponsor and Fujifilm shall establish a Joint Steering Committee (the “Joint Steering Committee” or “JSC”) comprised of Program
Managers and functional leaders from both Parties (and Sponsor’s Commercial Partners upon mutual agreement by both Parties). 

  

	 	b)	Program Managers. Each Party shall appoint one person to serve as a Program Manager with responsibility for overseeing program execution and being the primary point of contact between the Parties with respect to
the Program. 

  

	 	c)	Replacement of Joint Steering Committee Representatives and Program Managers. Each Party shall be free to replace its representative members on the Joint Steering Committee or its Program Manager with new
appointees who have authority to act on behalf of such Party, on notice to the other Party. 

  

	 	d)	Responsibilities of Joint Steering Committee. The Joint Steering Committee shall be responsible for overseeing and directing the Parties’ interaction and performance of their respective obligations under
this Agreement. Without limiting the generality of the foregoing, its duties shall include: 

  

			
	CONFIDENTIAL	  	25
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	i.	monitoring the performance of the Program; 

  

	 	ii.	resolving disagreements that arise under the Agreement; and 

  

	 	iii.	determining the need for and terms of any Change Orders. 

  

	 	e)	Meetings. The Joint Steering Committee shall define meeting frequency, timing and location in order to monitor Programs and resolve issues arising hereunder and to perform its responsibilities under this
Agreement. Such meetings may be in person or by telephone as agreed by the Joint Steering Committee. As required, the Joint Steering Committee meetings may include additional relevant function leaders from Sponsor and Fujifilm. 

 

	 	f)	Minutes. Within fifteen (15) days after each Joint Steering Committee meeting, the Program Manager shall prepare and distribute minutes of the meeting, which shall summarize the discussion points, actions,
and decisions made by the Joint Steering Committee. Program Managers from Fujifilm and Sponsor shall alternate preparing meeting minutes, unless the JSC decides otherwise. Minutes shall be approved or disapproved and revised, as necessary, at the
next minutes. Final minutes shall be distributed to the members of the Joint Steering Committee. 

  

	 	g)	Dispute Resolution. In the event that the Joint Steering Committee cannot reach agreement with respect to any material issue, then the issue shall be resolved in accordance with the dispute resolution provisions
in Section 15. 

  

	 	h)	Limitations. The Joint Steering Committee is not empowered to amend the terms of this Agreement. 

Section 27 
 Assignment 

This Agreement shall not be assigned in whole or in part by either Party without the prior written consent of the other, which consent shall not be
unreasonably withheld or delayed. Any attempt to assign this Agreement without such consent shall be void and of no effect. Notwithstanding the foregoing, either Party shall be entitled, without the prior written consent of the other Party, to
assign all or a part of its rights under this Agreement to a purchaser of all or substantially all of its assets, or an entity with which it may merge where it is not the surviving company, provided that the assignee agrees in writing to assume all
obligations undertaken by its assignor in this Agreement. No assignment shall relieve the assigning Party of responsibility for the performance of any of its obligations hereunder. The terms of this Agreement shall inure to the benefit of successors
and assigns. 
 Section 28 
 Notice 

All notices to be given as required in this Agreement shall be in writing and shall be delivered personally, sent by telecopies, or mailed either by a
reputable overnight carrier or first class mail, postage prepaid to the Parties at the addresses set forth below or such other addresses as the Parties may designate in writing. Such notice shall be effective on the date sent, if delivered
personally or sent by facsimile, the date after delivery if sent by overnight carrier and on the date received if mailed first class. 

  

			
	CONFIDENTIAL	  	26
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 If to Sponsor: 

General Manager 
 William L. Griffin 

BioMimetic Therapeutics, LLC 
 389 Nichol Mill Ln 

Franklin, TN 37067 
 With copy to: 

General Counsel 
 Wright Medical Technology, Inc. 

1023 Cherry Road 
 Memphis, TN 38117 

If to Fujifilm: 
 President 

Fujifilm Diosynth Biotechnologies 
 101 J. Morris Commons Lane

 Morrisville, NC 27560 
 P: 919-337-4400 

F: 919-337-0899 
 With copies to: 

General Counsel 
 Legal Department 

FUJIFILM Holdings America Corporation 
 200 Summit Lake Drive 

Valhalla, New York 10595-1356 
 F: 914-789-8514 

Section 29 
 Choice of Law 

This Agreement shall be construed and enforced in accordance with the laws of and in the venue of the State of North Carolina except for its rules regarding
conflict of laws. 
 Section 30 

Waiver/Severability 
 No waiver of any provision of
this Agreement, whether by conduct or otherwise, in any one or more instances shall be deemed to be or be construed as a further or continuing waiver of any such provision, or of any other provision or condition of this Agreement. If any provisions
hereof shall be determined to be invalid or unenforceable, the validity and effect of the other provisions of this Agreement shall not be affected thereby. 

Section 31 
 Nonsolicitation 

For the term of this Agreement, and for [***] following termination of this Agreement, for any reason, neither Sponsor nor Fujifilm nor any of their employees
or agents shall, directly or indirectly, solicit, hire, or attempt to solicit or hire, any employees of the other who were involved in the Program, unless otherwise approved by the other Party. 

  

			
	CONFIDENTIAL	  	27
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 Section 32 

Business Continuity and Disaster Recovery Plan; Site Master File 
  

	 	a)	Fujifilm shall develop and make effective prior to or upon execution of this Agreement, a written [***] for the manufacturing and storage facilities used to produce and store Drug Substance or Intermediate pursuant to
this Agreement. 

  

	 	b)	Fujifilm shall maintain a Site Master File with FDA as specified in the Quality Agreement. 

 Section 33

 Entire Agreement; Modification/Counterparts 
  

	 	a)	Entire Agreement/Modification. This instrument including the attached Appendices sets forth the entire agreement between the Parties hereto with respect to the performance of the Program by Fujifilm for Sponsor
and as such, supersedes all prior and contemporaneous negotiations, agreements, representations, understandings, and commitments with respect thereto and shall take precedence over all terms, conditions and provisions on any purchase order form or
form of order acknowledgment or other document purporting to address the same subject matter. This Agreement shall not be waived, released, discharged, changed or modified in any manner except by an instrument signed by the duly authorized officers
of each of the Parties hereto, which instrument shall make specific reference to this Agreement and shall express the plan or intention to modify same. 

  

	 	b)	Counterparts. This Agreement may be executed in one or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

Section 34 
 [***] Due to Changes in
[***] 
 In the event, during the manufacture of engineering or cGMP batches under the MBSA, the Parties discover information which
requires changes to the [***] related to the [***], the Parties shall, in good faith, [***] of this Agreement to reflect a shared risk allocation for implementing a [***] under this Agreement. 

Section 35 
 Limitation of Fujifilm’s Liability
in Sponsor Agreements with Drug Substance Recipients. 
 The Parties acknowledge and agree that Sponsor shall be distributing Drug Substance to
third-parties with whom Fujifilm shall not have a contractual relationship. Sponsor shall include provisions in its contracts with any such recipients of Drug Substance to ensure that Fujifilm shall not have any liability to any such recipients of
Drug Substance with whom Fujifilm does not have a direct contractual relationship. Without limiting the foregoing, Sponsor shall disclaim, in all such contracts, all of Fujifilm’s warranties, express or implied, including without limitation,
warranties of merchantability and fitness for use, and shall disclaim Fujifilm’s liability for direct, indirect, consequential, incidental, punitive and special damages. Sponsor shall name Fujifilm as a third party beneficiary to disclaimers of
warranties and liabilities described in this Section 35 in its agreements with such Drug Substance recipients. To the extent Sponsor is unable to secure the protections for Fujifilm as set forth in this Section 35, Sponsor shall indemnify,
defend and hold harmless Fujifilm, its affiliates and each of their respective officers, directors, employees and agents against any and loss, cost, damage or expense from any lawsuit, action, claim, demand, assessment or proceeding made by such
third party Drug Substance recipients related to the Drug Substance. 

  

			
	CONFIDENTIAL	  	28
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 [Signature Page to Follow] 

  

			
	CONFIDENTIAL	  	29
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

									
			
	BioMimetic Therapeutics, LLC	 		 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
	By:	 	 /s/ William L. Griffin
	 		 	By:	 	 /s/ Vincent Romeo

					
	Name:	 	 William L. Griffin
	 		 	Name:	 	 Vincent Romeo

					
	Title:	 	 EVP and GM
	 		 	Title:	 	 CFO

					
	Date:	 	 April 4, 2016
	 		 	Date:	 	 March 30, 2016

				
		 		 		 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
		 		 		 	By:	 	 /s/ M. E. Meeson

					
		 		 		 	Name:	 	 M. E. Meeson

					
		 		 		 	Title:	 	 President

					
		 		 		 	Date:	 	 March 30, 2016

  

			
	CONFIDENTIAL	  	30
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 Attachment 1: Service Price 

Table 1 
  

			
	 MANUFACTURING PRICE

	 Manufacturing Price
	  	
	 A. [***]
	  	$[***] per Batch
	 B. [***]
	  	$[***] per Batch
	 C. [***]
	  	$[***] per Batch
	 D. [***]
	  	$[***] per Batch

 Table 2 
  

			
	 CAMPAIGN REPORT FEE
	  	$[***] per
campaign report
	
	 Campaign Report

	
	 •  Collection of process surveillance parameters data for all Batches
Manufactured at Fujifilm. Surveillance parameters include but are not limited to Critical Parameters and In-Process Controls

	
	 •  Trending of Surveillance Parameters

	
	 •  Statistical Analysis shall be performed on Critical Process and
Quality Attributes at a minimum

	
	 •  Regulatory/QA support for periodic review of surveillance parameter
data in compliance with US, EU, and Canadian regulations.

	
	 •  Preparation of surveillance parameter data report after completion
of each manufacturing campaign

	
	 Note: Surveillance review in compliance with regulatory requirements outside the
above listed may incur in additional costs

  

			
	CONFIDENTIAL	  	31
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 Table 3 
  

			
	 ANNUAL PROGRAM FEE
	  	$[***] per year
	 Annual Product Quality Review (APR) Report

	
	 •    The purpose of Product Quality Review is to evaluate if
the process is operating consistently within its validated state, to determine if there is a need for specification revision, to highlight trends and identify any needed corrective action, process improvement and/or re-validation.

	
	 •    The Product Quality Review (PQR) covers activities
performed by the RTP Facility or subcontracted by

	
	 RTP Facility (e.g. Stability and/or Raw Material testing) and which occurred during
the PQR review period.

	
	 •    Quality Assurance compiles the submitted information
into a Fujifilm report format.

	
	 Note: the report will be issued following Fujifilm standard template, price may
adjust if significant changes requested

	
	 Annual Regulatory Support

	
	Annual documentation support for repeat regulatory requirements in accordance to US, EU, and Canadian regulation. Activities include:
	
	 •    Review and comments on all regulatory submissions (as
related to Product)

	
	 •    Inspection support and responses to any observations
directly related to Manufacture of Product

	
	 •    Updates to regulatory submissions, including support for
supplements, variations and annual reports

	
	 •    Site master file updates

 Table 4 
  

			
	 ENGINEERING RUN PRICE

		
	 Engineering Run Price
	  	$[***] per Run
		  	

  

			
	CONFIDENTIAL	  	32
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 Attachment 2: Process Consumables Lists 

Lists of Process Consumables Category A, B and C. Pricing will be Fujifilm’s cost of such Process Consumables purchased under the terms of the Agreement
plus a [***] handling fee. 
 Category A 
 Process
Consumables listed in Manufacturing documentation and held by Fujifilm in its common stock. 
 Category B 

 

					
	 Fujifilm Item Spec #
	 	 	  	Description
	 [***]
	 		  	[***]
	 [***]
	 		  	[***]
	 [***]
	 		  	[***]

 Category C 
  

					
	 Fujifilm Item Spec #
	 	 	  	Description
	 [***]
	 		  	[***]
	 [***]
	 		  	[***]
	 [***]
	 		  	[***]

  

			
	CONFIDENTIAL	  	33
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 Attachment 3: Allocation of Drug Substance between Sponsor and Commercial Partners 

 

	 	1.	During the Annual Planning Meeting, Parties shall agree on the allocation of Drug Substance resulting from and payments for Batches Manufactured under Binding Orders. For clarity, such allocated payments will include
all invoices from Fujifilm related to performance of the Agreement during the planned calendar year under Binding Order, including but not limited to payments for Batches manufactured under Binding Order, campaign fees, annual fees, and payments for
Process Consumables Category C Parties shall make such allocation between Sponsor and its Commercial Partners according to the following mechanism that may be modified from time to time by a written agreement of Parties: 

 

	 	a.	Sponsor and each of its Commercial Partners shall provide a [***] Forecast, as specified in Section 4e), reflecting required quantity of Drug Substance and expected number of Batches to deliver such quantity. The
required quantity of Drug Substance will be the basis to calculate the percent of allocation of Drug Substance between Sponsor and Commercial Partners (“Percent Allocated”). The number of Batches in the forecast that correspond to the
forecasted number of grams will be for planning purposes only and will be verified jointly by Parties during the Annual Planning Meeting, as specified in paragraph 2 below. 

 

	 	b.	Percent Allocated will be calculated according to the following formulas: 

 Percent
Allocated to Sponsor = (number of grams forecasted by Sponsor) / (number of grams forecasted by Sponsor and all Commercial Partners) 

Percent Allocated to a Commercial Partner = (number of grams forecasted by such Commercial Partner) / (number of grams forecasted by
Sponsor and all Commercial Partners) 
  

	 	c.	Parties may agree on Percent(s) Allocated that is different than the number calculated according to equations in 1b. Percent Allocated shall be documented in meeting minutes and will be used by Fujifilm to allocate
payment responsibility and Drug Substance produced. 

  

	 	d.	Sponsor and its Commercial Partners will be responsible for all payments due under this Agreement in accordance with their Percent Allocated. For each payment due under Section 9, Fujifilm shall issue separate
invoices to Sponsor and each of the Commercial Partners in amount commensurate with their Percent Allocated, 

Example1: [***] 
  

	 	2.	The number of Batches to be manufactured under Binding Order shall be calculated by dividing the total number of grams forecasted by Sponsor and each of its Commercial Partners by an average expected Product yield per
Batch, rounded up to a full Batch. Parties may agree to manufacture more Batches than calculated. The average expected Product yield used for such calculations shall be documented in the meeting minutes. 

  

			
	CONFIDENTIAL	  	34
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

	 	3.	For clarity, payment obligations of Sponsor and its Commercial Partners are based on the number of Batches produced and not on the actual quantity of Product Manufactured. Sponsor and its Commercial Partners shall take
possession of all Drug Substance Manufactured irrespectively if the quantity (in grams) meets or exceeds their [***] Forecast. 

  

	 	4.	Drug Substance from Batches manufactured under Binding Order shall be split between Sponsor and its Commercial Partners according to Percent Allocated, as outlined below: 

 

	 	a.	Product shall be allocated in increments of full containers (bottles). 

  

	 	b.	Unless otherwise instructed in writing by Sponsor prior to delivery as specified in Section 16, any partial containers, or containers that are left after allocation shall be delivered to Sponsor. 

Example 2: [***] 
  

	 	5.	After completion of the Manufacturing Campaign for any given year and review of Product yield but before disposition of the last Batch from the Campaign, Sponsor and its Commercial Partners Parties may request that Drug
Substance produced is split differently between Sponsor and is Commercial Partners. Sponsor shall be responsible for providing Fujifilm with detail guidance on such split. Change in how actually produced Drug Substance is split between Sponsor and
Commercial Partners shall not change the Percent Allocated in relation to Parties’ payment obligations towards Fujifilm. 

Example 3: [***] 
  

	 	6.	Sponsor or one of its Commercial Partners may request that Fujifilm manufactures additional Batches of Product, for their own use only, within the already scheduled and allocated Manufacturing Campaign. Such additional
Batches are not subject to allocation of Product and payments based on Percent Allocated for other batches in the same Campaign. The ordering Party is solely responsible for payments for the additional Batches at the same Manufacturing Price as
other Batches Manufactured in the same campaign under the Binding Order. Adding Batches to an already allocated Manufacturing Campaign will not change allocation of payments in relation to performance of the Agreement during the planned calendar
year, including but not limited to payments for Batches manufactured under Binding Order, campaign fees, annual fees, and payments for Process Consumables Category C. Batches manufactured under the Binding Order, the Campaign Report Fee, Annual
Program fees unless the ordering Party requires a separate report, which would be subject to an additional payment. 

  

			
	CONFIDENTIAL	  	35
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.	  	

 FDBU-BMT Commercial Supply Agreement 

 

 Attachment 4: Sponsor’s Commercial Partners and Other Drug Substance Recipients

 Table 5. Recipients of Drug Substance 
  

													
	 	  	 Company
	  	 Designated as
Sponsor’s
Commercial
Partner
	  	 Party to Annual
Meeting
	  	 Party to JSC
	  	 Independent Supply
Agreement with
Fujifilm
	  	 Who Supplies Drug
Substance
to
the Company

	1	  	[***]	  	[***]	  	YES	  	[***]	  	[***]	  	[***]
	2	  	[***]	  	[***]	  	NO	  	[***]	  	[***]	  	[***]

  

			
	CONFIDENTIAL	  	36
	[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]